HRP20201539T1 - Pozitivni alosterni modulatori muskarinskog m1 receptora - Google Patents
Pozitivni alosterni modulatori muskarinskog m1 receptora Download PDFInfo
- Publication number
- HRP20201539T1 HRP20201539T1 HRP20201539TT HRP20201539T HRP20201539T1 HR P20201539 T1 HRP20201539 T1 HR P20201539T1 HR P20201539T T HRP20201539T T HR P20201539TT HR P20201539 T HRP20201539 T HR P20201539T HR P20201539 T1 HRP20201539 T1 HR P20201539T1
- Authority
- HR
- Croatia
- Prior art keywords
- carboxamide
- hydroxytetrahydropyran
- methyl
- pyridine
- pyrrolo
- Prior art date
Links
- 102000007207 Muscarinic M1 Receptor Human genes 0.000 title claims 3
- 108010008406 Muscarinic M1 Receptor Proteins 0.000 title claims 3
- 230000003281 allosteric effect Effects 0.000 title 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 13
- 206010012289 Dementia Diseases 0.000 claims 12
- 150000001875 compounds Chemical class 0.000 claims 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- 125000005843 halogen group Chemical group 0.000 claims 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims 6
- 229910052736 halogen Inorganic materials 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- SYAQMBXTBOSJGI-SJLPKXTDSA-N 8-[(4-fluorophenyl)methyl]-N-[(3S,4R)-3-hydroxyoxan-4-yl]-4-methyl-2,3-dihydropyrido[3,2-b][1,4]oxazine-6-carboxamide Chemical compound CN1CCOc2c(Cc3ccc(F)cc3)cc(nc12)C(=O)N[C@@H]1CCOC[C@H]1O SYAQMBXTBOSJGI-SJLPKXTDSA-N 0.000 claims 4
- 208000010877 cognitive disease Diseases 0.000 claims 4
- 125000002971 oxazolyl group Chemical group 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 125000003226 pyrazolyl group Chemical group 0.000 claims 4
- 125000004076 pyridyl group Chemical group 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 4
- 125000000335 thiazolyl group Chemical group 0.000 claims 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 3
- GOOIJWJUBCHXED-SJLPKXTDSA-N 4-[(2,3-difluorophenyl)methyl]-N-[(3S,4R)-3-hydroxyoxan-4-yl]-1-methylpyrrolo[2,3-b]pyridine-6-carboxamide Chemical compound O[C@@H]1COCC[C@H]1NC(=O)C1=CC(=C2C(=N1)N(C=C2)C)CC1=C(C(=CC=C1)F)F GOOIJWJUBCHXED-SJLPKXTDSA-N 0.000 claims 3
- PJARMRULPDCMTF-NVXWUHKLSA-N 4-[(2-fluoropyridin-4-yl)methyl]-N-[(3S,4R)-3-hydroxyoxan-4-yl]-1-methylpyrrolo[2,3-b]pyridine-6-carboxamide Chemical compound O[C@@H]1COCC[C@H]1NC(=O)C1=CC(=C2C(=N1)N(C=C2)C)CC1=CC(=NC=C1)F PJARMRULPDCMTF-NVXWUHKLSA-N 0.000 claims 3
- BSIWIMPDGNURNF-IEBWSBKVSA-N 4-[(3,4-difluorophenyl)methyl]-N-[(3S,4R)-3-hydroxyoxan-4-yl]-1-methylpyrrolo[2,3-b]pyridine-6-carboxamide Chemical compound O[C@@H]1COCC[C@H]1NC(=O)C1=CC(=C2C(=N1)N(C=C2)C)CC1=CC(=C(C=C1)F)F BSIWIMPDGNURNF-IEBWSBKVSA-N 0.000 claims 3
- MYECJYAHUOIOPO-IEBWSBKVSA-N 4-[(3-fluorophenyl)methyl]-N-[(3S,4R)-3-hydroxyoxan-4-yl]-1-methylpyrrolo[2,3-b]pyridine-6-carboxamide Chemical compound O[C@@H]1COCC[C@H]1NC(=O)C1=CC(=C2C(=N1)N(C=C2)C)CC1=CC(=CC=C1)F MYECJYAHUOIOPO-IEBWSBKVSA-N 0.000 claims 3
- DAHZPDDJHWPINK-RTBURBONSA-N 4-[(4-fluorophenyl)methyl]-N-[(3R,4R)-4-hydroxyoxan-3-yl]-1-methylpyrrolo[2,3-b]pyridine-6-carboxamide Chemical compound O[C@H]1[C@@H](COCC1)NC(=O)C1=CC(=C2C(=N1)N(C=C2)C)CC1=CC=C(C=C1)F DAHZPDDJHWPINK-RTBURBONSA-N 0.000 claims 3
- AXSSVGSLIPAGNA-WOJBJXKFSA-N 4-[(4-fluorophenyl)methyl]-N-[(3R,4R)-4-hydroxyoxan-3-yl]-5,6,7,8-tetrahydro-1,7-naphthyridine-2-carboxamide Chemical compound O[C@H]1[C@@H](COCC1)NC(=O)C1=NC=2CNCCC=2C(=C1)CC1=CC=C(C=C1)F AXSSVGSLIPAGNA-WOJBJXKFSA-N 0.000 claims 3
- JGHPPURPDSRMKG-GZJHNZOKSA-N 4-[(4-fluorophenyl)methyl]-N-[(3R,4R)-4-hydroxyoxan-3-yl]-5,6,7,8-tetrahydro-1,7-naphthyridine-2-carboxamide hydrochloride Chemical compound Cl.O[C@H]1[C@@H](COCC1)NC(=O)C1=NC=2CNCCC2C(=C1)CC1=CC=C(C=C1)F JGHPPURPDSRMKG-GZJHNZOKSA-N 0.000 claims 3
- UANWNQVZOHQTMM-IEBWSBKVSA-N 4-[(4-fluorophenyl)methyl]-N-[(3S,4R)-3-hydroxyoxan-4-yl]-1-methylpyrrolo[2,3-b]pyridine-6-carboxamide Chemical compound O[C@@H]1COCC[C@H]1NC(=O)C1=CC(=C2C(=N1)N(C=C2)C)CC1=CC=C(C=C1)F UANWNQVZOHQTMM-IEBWSBKVSA-N 0.000 claims 3
- OCMORMXZYBEYKX-YLJYHZDGSA-N 4-[(4-fluorophenyl)methyl]-N-[(3S,4R)-3-hydroxyoxan-4-yl]-5,6,7,8-tetrahydro-1,7-naphthyridine-2-carboxamide Chemical compound O[C@@H]1COCC[C@H]1NC(=O)c1cc(Cc2ccc(F)cc2)c2CCNCc2n1 OCMORMXZYBEYKX-YLJYHZDGSA-N 0.000 claims 3
- UIRWSGXKDKVFBH-OGPPPPIKSA-N 4-[(4-fluorophenyl)methyl]-N-[(3S,4R)-3-hydroxyoxan-4-yl]-5,6,7,8-tetrahydro-1,7-naphthyridine-2-carboxamide hydrochloride Chemical compound Cl.O[C@@H]1COCC[C@H]1NC(=O)C1=NC=2CNCCC2C(=C1)CC1=CC=C(C=C1)F UIRWSGXKDKVFBH-OGPPPPIKSA-N 0.000 claims 3
- CRVCXUAHXPMOOY-NVXWUHKLSA-N 4-[(6-chloropyridin-3-yl)methyl]-N-[(3S,4R)-3-hydroxyoxan-4-yl]-1-methylpyrrolo[2,3-b]pyridine-6-carboxamide Chemical compound O[C@@H]1COCC[C@H]1NC(=O)C1=CC(=C2C(=N1)N(C=C2)C)CC=1C=CC(=NC=1)Cl CRVCXUAHXPMOOY-NVXWUHKLSA-N 0.000 claims 3
- OUWAOIBOLRRNNE-RHSMWYFYSA-N 7-[(6-chloropyridin-3-yl)methyl]-N-[(3S,4R)-3-hydroxyoxan-4-yl]-1-methylpyrrolo[3,2-b]pyridine-5-carboxamide Chemical compound O[C@@H]1COCC[C@H]1NC(=O)C1=CC(=C2C(=N1)C=CN2C)CC=1C=CC(=NC=1)Cl OUWAOIBOLRRNNE-RHSMWYFYSA-N 0.000 claims 3
- NRGNOVBNXFAJJW-NVXWUHKLSA-N 8-[(4-fluorophenyl)methyl]-N-[(3S,4R)-3-hydroxyoxan-4-yl]-2,3-dihydro-[1,4]dioxino[2,3-b]pyridine-6-carboxamide Chemical compound O[C@@H]1COCC[C@H]1NC(=O)C1=CC(=C2C(=N1)OCCO2)CC1=CC=C(C=C1)F NRGNOVBNXFAJJW-NVXWUHKLSA-N 0.000 claims 3
- MXMSQEZQGXLQEC-RTBURBONSA-N N-[(3R,4R)-4-hydroxyoxan-3-yl]-1-methyl-4-[(6-methylpyridin-3-yl)methyl]pyrrolo[2,3-b]pyridine-6-carboxamide Chemical compound O[C@H]1[C@@H](COCC1)NC(=O)C1=CC(=C2C(=N1)N(C=C2)C)CC=1C=CC(=NC=1)C MXMSQEZQGXLQEC-RTBURBONSA-N 0.000 claims 3
- HPSMVSQUFDRDLH-WOJBJXKFSA-N N-[(3R,4R)-4-hydroxyoxan-3-yl]-4-[(4-methoxyphenyl)methyl]-1-methylpyrrolo[2,3-b]pyridine-6-carboxamide Chemical compound O[C@H]1[C@@H](COCC1)NC(=O)C1=CC(=C2C(=N1)N(C=C2)C)CC1=CC=C(C=C1)OC HPSMVSQUFDRDLH-WOJBJXKFSA-N 0.000 claims 3
- CIQYFXIRLSUJBJ-DHIUTWEWSA-N N-[(3R,4R)-4-hydroxyoxan-3-yl]-4-[(4-pyrazol-1-ylphenyl)methyl]-5,6,7,8-tetrahydro-1,7-naphthyridine-2-carboxamide Chemical compound O[C@H]1[C@@H](COCC1)NC(=O)C1=NC=2CNCCC=2C(=C1)CC1=CC=C(C=C1)N1N=CC=C1 CIQYFXIRLSUJBJ-DHIUTWEWSA-N 0.000 claims 3
- QQKJVZFNVODJHV-OHIDFYLOSA-N N-[(3R,4R)-4-hydroxyoxan-3-yl]-4-[(4-pyrazol-1-ylphenyl)methyl]-5,6,7,8-tetrahydro-1,7-naphthyridine-2-carboxamide hydrochloride Chemical compound Cl.O[C@H]1[C@@H](COCC1)NC(=O)C1=NC=2CNCCC2C(=C1)CC1=CC=C(C=C1)N1N=CC=C1 QQKJVZFNVODJHV-OHIDFYLOSA-N 0.000 claims 3
- CNIMNXMKTIMBBY-DENIHFKCSA-N N-[(3S,4R)-3-hydroxyoxan-4-yl]-1-methyl-4-[[4-(1,3-thiazol-4-yl)phenyl]methyl]pyrrolo[2,3-b]pyridine-6-carboxamide Chemical compound O[C@@H]1COCC[C@H]1NC(=O)C1=CC(=C2C(=N1)N(C=C2)C)CC1=CC=C(C=C1)C=1N=CSC=1 CNIMNXMKTIMBBY-DENIHFKCSA-N 0.000 claims 3
- WXRLXFKXNNYQDP-FYYLOGMGSA-N N-[(3S,4R)-3-hydroxyoxan-4-yl]-1-methyl-4-[[4-(1-methylpyrazol-4-yl)phenyl]methyl]pyrrolo[2,3-b]pyridine-6-carboxamide Chemical compound O[C@@H]1COCC[C@H]1NC(=O)C1=CC(=C2C(=N1)N(C=C2)C)CC1=CC=C(C=C1)C=1C=NN(C=1)C WXRLXFKXNNYQDP-FYYLOGMGSA-N 0.000 claims 3
- GRIASIMLEHEHDS-UYAOXDASSA-N N-[(3S,4R)-3-hydroxyoxan-4-yl]-4-[(4-methoxyphenyl)methyl]-1-methylpyrrolo[2,3-b]pyridine-6-carboxamide Chemical compound O[C@@H]1COCC[C@H]1NC(=O)C1=CC(=C2C(=N1)N(C=C2)C)CC1=CC=C(C=C1)OC GRIASIMLEHEHDS-UYAOXDASSA-N 0.000 claims 3
- IEEHGDLCFCOXQC-NFBKMPQASA-N N-[(3S,4R)-3-hydroxyoxan-4-yl]-4-[(4-pyrazol-1-ylphenyl)methyl]-5,6,7,8-tetrahydro-1,7-naphthyridine-2-carboxamide Chemical compound O[C@@H]1COCC[C@H]1NC(=O)c1cc(Cc2ccc(cc2)-n2cccn2)c2CCNCc2n1 IEEHGDLCFCOXQC-NFBKMPQASA-N 0.000 claims 3
- KAVBGUDLZITHHL-KFWGXXPESA-N N-[(3S,4R)-3-hydroxyoxan-4-yl]-4-[(4-pyrazol-1-ylphenyl)methyl]-5,6,7,8-tetrahydro-1,7-naphthyridine-2-carboxamide hydrochloride Chemical compound C1COC[C@H]([C@@H]1NC(=O)C2=NC3=C(CCNC3)C(=C2)CC4=CC=C(C=C4)N5C=CC=N5)O.Cl KAVBGUDLZITHHL-KFWGXXPESA-N 0.000 claims 3
- NEXIUBBVPBZESN-AUSIDOKSSA-N N-[(3S,4R)-3-hydroxyoxan-4-yl]-4-[[4-(1,3-thiazol-4-yl)phenyl]methyl]-5,6,7,8-tetrahydro-1,7-naphthyridine-2-carboxamide Chemical compound O[C@@H]1COCC[C@H]1NC(=O)c1cc(Cc2ccc(cc2)-c2cscn2)c2CCNCc2n1 NEXIUBBVPBZESN-AUSIDOKSSA-N 0.000 claims 3
- IOVZYPBXWNNSLW-AQHBPOCSSA-N N-[(3S,4R)-3-hydroxyoxan-4-yl]-4-[[4-(1,3-thiazol-4-yl)phenyl]methyl]-5,6,7,8-tetrahydro-1,7-naphthyridine-2-carboxamide hydrochloride Chemical compound Cl.O[C@@H]1COCC[C@H]1NC(=O)C1=NC=2CNCCC2C(=C1)CC1=CC=C(C=C1)C=1N=CSC1 IOVZYPBXWNNSLW-AQHBPOCSSA-N 0.000 claims 3
- NYUCEIXWAIVRPS-IEBWSBKVSA-N O[C@@H]1COCC[C@H]1NC(=O)C=1C=C(C=2OCCN(C=2N=1)C)CC1=CC=C(C=C1)OC Chemical compound O[C@@H]1COCC[C@H]1NC(=O)C=1C=C(C=2OCCN(C=2N=1)C)CC1=CC=C(C=C1)OC NYUCEIXWAIVRPS-IEBWSBKVSA-N 0.000 claims 3
- 208000027520 Somatoform disease Diseases 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 208000027753 pain disease Diseases 0.000 claims 3
- 208000019116 sleep disease Diseases 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 claims 2
- 230000000155 isotopic effect Effects 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- CHNYIWLAURARBT-HKUYNNGSSA-N 1-ethyl-4-[(2-fluoropyridin-4-yl)methyl]-N-[(1S,2S)-2-hydroxycyclohexyl]pyrrolo[2,3-b]pyridine-6-carboxamide Chemical compound O[C@@H]1[C@H](CCCC1)NC(=O)C1=CC(=C2C(=N1)N(C=C2)CC)CC1=CC(=NC=C1)F CHNYIWLAURARBT-HKUYNNGSSA-N 0.000 claims 1
- ZMIPOECMISFYOU-PXNSSMCTSA-N 4-(1,3-benzothiazol-6-ylmethyl)-N-[(1S,2S)-2-hydroxycyclohexyl]-1-methylpyrrolo[2,3-b]pyridine-6-carboxamide Chemical compound O[C@@H]1[C@H](CCCC1)NC(=O)C1=CC(=C2C(=N1)N(C=C2)C)CC1=CC2=C(N=CS2)C=C1 ZMIPOECMISFYOU-PXNSSMCTSA-N 0.000 claims 1
- OORIUQFXVDGTGM-HKUYNNGSSA-N 4-[(2,3-difluorophenyl)methyl]-N-[(1S,2S)-2-hydroxycyclohexyl]-1,3-dimethylpyrrolo[2,3-b]pyridine-6-carboxamide Chemical compound CN1C=C(C)C2=C1N=C(C=C2CC1=C(F)C(F)=CC=C1)C(=O)N[C@H]1CCCC[C@@H]1O OORIUQFXVDGTGM-HKUYNNGSSA-N 0.000 claims 1
- HDAWTKATDSUWIF-HKUYNNGSSA-N 4-[(2,3-difluorophenyl)methyl]-N-[(1S,2S)-2-hydroxycyclohexyl]-1-methyl-2,3-dihydropyrrolo[2,3-b]pyridine-6-carboxamide Chemical compound O[C@@H]1[C@H](CCCC1)NC(=O)C1=CC(=C2C(=N1)N(CC2)C)CC1=C(C(=CC=C1)F)F HDAWTKATDSUWIF-HKUYNNGSSA-N 0.000 claims 1
- QHOQGZWNVXBOMF-HKUYNNGSSA-N 4-[(2,3-difluorophenyl)methyl]-N-[(1S,2S)-2-hydroxycyclohexyl]-1-methylpyrrolo[2,3-b]pyridine-6-carboxamide Chemical compound O[C@@H]1[C@H](CCCC1)NC(=O)C1=CC(=C2C(=N1)N(C=C2)C)CC1=C(C(=CC=C1)F)F QHOQGZWNVXBOMF-HKUYNNGSSA-N 0.000 claims 1
- DNTLPINCBYERPF-WMZOPIPTSA-N 4-[(2,5-difluoropyridin-4-yl)methyl]-N-[(1S,2S)-2-hydroxycyclohexyl]-1-methylpyrrolo[2,3-b]pyridine-6-carboxamide Chemical compound O[C@@H]1[C@H](CCCC1)NC(=O)C1=CC(=C2C(=N1)N(C=C2)C)CC1=CC(=NC=C1F)F DNTLPINCBYERPF-WMZOPIPTSA-N 0.000 claims 1
- YOPHHNMWTZYKDJ-WMZOPIPTSA-N 4-[(2-chloropyridin-4-yl)methyl]-N-[(1S,2S)-2-hydroxycyclohexyl]-1-methylpyrrolo[2,3-b]pyridine-6-carboxamide Chemical compound O[C@@H]1[C@H](CCCC1)NC(=O)C1=CC(=C2C(=N1)N(C=C2)C)CC1=CC(=NC=C1)Cl YOPHHNMWTZYKDJ-WMZOPIPTSA-N 0.000 claims 1
- QKXNXNBIQDXBSD-WMZOPIPTSA-N 4-[(2-fluoropyridin-4-yl)methyl]-N-[(1S,2S)-2-hydroxycyclohexyl]-1-methyl-2,3-dihydropyrrolo[2,3-b]pyridine-6-carboxamide Chemical compound O[C@@H]1[C@H](CCCC1)NC(=O)C1=CC(=C2C(=N1)N(CC2)C)CC1=CC(=NC=C1)F QKXNXNBIQDXBSD-WMZOPIPTSA-N 0.000 claims 1
- KCHMOJHULZXJTF-WMZOPIPTSA-N 4-[(2-fluoropyridin-4-yl)methyl]-N-[(1S,2S)-2-hydroxycyclohexyl]-1-methylpyrrolo[2,3-b]pyridine-6-carboxamide Chemical compound O[C@@H]1[C@H](CCCC1)NC(=O)C1=CC(=C2C(=N1)N(C=C2)C)CC1=CC(=NC=C1)F KCHMOJHULZXJTF-WMZOPIPTSA-N 0.000 claims 1
- FEDPVEABZFSYNV-ICSRJNTNSA-N 4-[(2-fluoropyridin-4-yl)methyl]-N-[(1S,2S)-2-hydroxycyclohexyl]-1-propan-2-ylpyrrolo[2,3-b]pyridine-6-carboxamide Chemical compound O[C@@H]1[C@H](CCCC1)NC(=O)C1=CC(=C2C(=N1)N(C=C2)C(C)C)CC1=CC(=NC=C1)F FEDPVEABZFSYNV-ICSRJNTNSA-N 0.000 claims 1
- VWIISSKYYQGECL-LPHOPBHVSA-N 4-[(2-fluoropyridin-4-yl)methyl]-N-[(1S,2S)-2-hydroxycyclohexyl]-5,6,7,8-tetrahydro-1,7-naphthyridine-2-carboxamide Chemical compound O[C@H]1CCCC[C@@H]1NC(=O)C1=CC(CC2=CC(F)=NC=C2)=C2CCNCC2=N1 VWIISSKYYQGECL-LPHOPBHVSA-N 0.000 claims 1
- BZILOAMBEYAKEF-QSVLQNJRSA-N 4-[(2-fluoropyridin-4-yl)methyl]-N-[(1S,2S)-2-hydroxycyclohexyl]-5,6,7,8-tetrahydro-1,7-naphthyridine-2-carboxamide hydrochloride Chemical compound Cl.O[C@@H]1[C@H](CCCC1)NC(=O)C1=NC=2CNCCC2C(=C1)CC1=CC(=NC=C1)F BZILOAMBEYAKEF-QSVLQNJRSA-N 0.000 claims 1
- GBUMNQWQLOEWCO-ICSRJNTNSA-N 4-[(3-fluorophenyl)methyl]-N-[(1S,2S)-2-hydroxycyclohexyl]-1-methylpyrrolo[2,3-b]pyridine-6-carboxamide Chemical compound O[C@@H]1[C@H](CCCC1)NC(=O)C1=CC(=C2C(=N1)N(C=C2)C)CC1=CC(=CC=C1)F GBUMNQWQLOEWCO-ICSRJNTNSA-N 0.000 claims 1
- XWUKLECWDZIPAS-RXVVDRJESA-N 4-[(3-fluorophenyl)methyl]-N-[(1S,2S)-2-hydroxycyclohexyl]-5,6,7,8-tetrahydro-1,7-naphthyridine-2-carboxamide Chemical compound O[C@H]1CCCC[C@@H]1NC(=O)C1=CC(CC2=CC(F)=CC=C2)=C2CCNCC2=N1 XWUKLECWDZIPAS-RXVVDRJESA-N 0.000 claims 1
- BXYJKJCAAIDYGP-ZXRBMNSTSA-N 4-[(3-fluorophenyl)methyl]-N-[(1S,2S)-2-hydroxycyclohexyl]-5,6,7,8-tetrahydro-1,7-naphthyridine-2-carboxamide hydrochloride Chemical compound Cl.O[C@@H]1[C@H](CCCC1)NC(=O)C1=NC=2CNCCC2C(=C1)CC1=CC(=CC=C1)F BXYJKJCAAIDYGP-ZXRBMNSTSA-N 0.000 claims 1
- KRQSAUAIRDBOGQ-RXVVDRJESA-N 4-[(4-chlorophenyl)methyl]-N-[(1S,2S)-2-hydroxycyclohexyl]-5,6,7,8-tetrahydro-1,7-naphthyridine-2-carboxamide Chemical compound O[C@H]1CCCC[C@@H]1NC(=O)C1=CC(CC2=CC=C(Cl)C=C2)=C2CCNCC2=N1 KRQSAUAIRDBOGQ-RXVVDRJESA-N 0.000 claims 1
- HJBKDRXLODQLMQ-ZXRBMNSTSA-N 4-[(4-chlorophenyl)methyl]-N-[(1S,2S)-2-hydroxycyclohexyl]-5,6,7,8-tetrahydro-1,7-naphthyridine-2-carboxamide hydrochloride Chemical compound Cl.O[C@@H]1[C@H](CCCC1)NC(=O)C1=NC=2CNCCC2C(=C1)CC1=CC=C(C=C1)Cl HJBKDRXLODQLMQ-ZXRBMNSTSA-N 0.000 claims 1
- GRZVDTXCTVOSIY-ICSRJNTNSA-N 4-[(4-fluorophenyl)methyl]-N-[(1S,2S)-2-hydroxycyclohexyl]-1-methyl-2,3-dihydropyrrolo[2,3-b]pyridine-6-carboxamide Chemical compound O[C@@H]1[C@H](CCCC1)NC(=O)C1=CC(=C2C(=N1)N(CC2)C)CC1=CC=C(C=C1)F GRZVDTXCTVOSIY-ICSRJNTNSA-N 0.000 claims 1
- UKEDFVOLVBQBTA-ICSRJNTNSA-N 4-[(4-fluorophenyl)methyl]-N-[(1S,2S)-2-hydroxycyclohexyl]-1-methylpyrrolo[2,3-b]pyridine-6-carboxamide Chemical compound O[C@@H]1[C@H](CCCC1)NC(=O)C1=CC(=C2C(=N1)N(C=C2)C)CC1=CC=C(C=C1)F UKEDFVOLVBQBTA-ICSRJNTNSA-N 0.000 claims 1
- KWYPYFIFFBCUMU-RXVVDRJESA-N 4-[(4-fluorophenyl)methyl]-N-[(1S,2S)-2-hydroxycyclohexyl]-5,6,7,8-tetrahydro-1,7-naphthyridine-2-carboxamide Chemical compound O[C@H]1CCCC[C@@H]1NC(=O)C1=CC(CC2=CC=C(F)C=C2)=C2CCNCC2=N1 KWYPYFIFFBCUMU-RXVVDRJESA-N 0.000 claims 1
- LJZYRCLIYDQJJR-ZXRBMNSTSA-N 4-[(4-fluorophenyl)methyl]-N-[(1S,2S)-2-hydroxycyclohexyl]-5,6,7,8-tetrahydro-1,7-naphthyridine-2-carboxamide hydrochloride Chemical compound Cl.O[C@@H]1[C@H](CCCC1)NC(=O)C1=NC=2CNCCC2C(=C1)CC1=CC=C(C=C1)F LJZYRCLIYDQJJR-ZXRBMNSTSA-N 0.000 claims 1
- SAJVSDXHRQEYAX-UGKGYDQZSA-N 4-[(4-fluorophenyl)methyl]-N-[(1S,2S)-2-hydroxycyclohexyl]-7-methyl-6,8-dihydro-5H-1,7-naphthyridine-2-carboxamide Chemical compound CN1CCC2=C(CC3=CC=C(F)C=C3)C=C(N=C2C1)C(=O)N[C@H]1CCCC[C@@H]1O SAJVSDXHRQEYAX-UGKGYDQZSA-N 0.000 claims 1
- GFGVRJBVOXCRAU-OALUTQOASA-N 4-[(4-fluorophenyl)methyl]-N-[(3S,4S)-4-hydroxyoxan-3-yl]-1-methyl-2,3-dihydropyrrolo[2,3-b]pyridine-6-carboxamide Chemical compound O[C@@H]1[C@H](COCC1)NC(=O)C1=CC(=C2C(=N1)N(CC2)C)CC1=CC=C(C=C1)F GFGVRJBVOXCRAU-OALUTQOASA-N 0.000 claims 1
- DAHZPDDJHWPINK-OALUTQOASA-N 4-[(4-fluorophenyl)methyl]-N-[(3S,4S)-4-hydroxyoxan-3-yl]-1-methylpyrrolo[2,3-b]pyridine-6-carboxamide Chemical compound CN1C=CC2=C1N=C(C=C2CC1=CC=C(F)C=C1)C(=O)N[C@H]1COCC[C@@H]1O DAHZPDDJHWPINK-OALUTQOASA-N 0.000 claims 1
- HAUNSAYXYHFAKQ-HKUYNNGSSA-N 4-[(6-chloropyridin-3-yl)methyl]-1-(2-fluoroethyl)-N-[(1S,2S)-2-hydroxycyclohexyl]pyrrolo[2,3-b]pyridine-6-carboxamide Chemical compound O[C@@H]1[C@H](CCCC1)NC(=O)C1=CC(=C2C(=N1)N(C=C2)CCF)CC=1C=CC(=NC=1)Cl HAUNSAYXYHFAKQ-HKUYNNGSSA-N 0.000 claims 1
- MPMFKLJJVKWSGS-WMZOPIPTSA-N 4-[(6-chloropyridin-3-yl)methyl]-N-[(1S,2S)-2-hydroxycyclohexyl]-1-methyl-2,3-dihydropyrrolo[2,3-b]pyridine-6-carboxamide Chemical compound O[C@@H]1[C@H](CCCC1)NC(=O)C1=CC(=C2C(=N1)N(CC2)C)CC=1C=CC(=NC=1)Cl MPMFKLJJVKWSGS-WMZOPIPTSA-N 0.000 claims 1
- ABELOGZNSVHLPG-WMZOPIPTSA-N 4-[(6-chloropyridin-3-yl)methyl]-N-[(1S,2S)-2-hydroxycyclohexyl]-1-methylpyrrolo[2,3-b]pyridine-6-carboxamide Chemical compound O[C@@H]1[C@H](CCCC1)NC(=O)C1=CC(=C2C(=N1)N(C=C2)C)CC=1C=CC(=NC=1)Cl ABELOGZNSVHLPG-WMZOPIPTSA-N 0.000 claims 1
- CVSVVQROOUFGOZ-UNMCSNQZSA-N 4-[(6-cyclopropylpyridin-3-yl)methyl]-N-[(1S,2S)-2-hydroxycyclohexyl]-1-methylpyrrolo[2,3-b]pyridine-6-carboxamide Chemical compound O[C@@H]1[C@H](CCCC1)NC(=O)C1=CC(=C2C(=N1)N(C=C2)C)CC=1C=CC(=NC=1)C1CC1 CVSVVQROOUFGOZ-UNMCSNQZSA-N 0.000 claims 1
- FQZFWEZFMXFNLY-WMZOPIPTSA-N 4-[(6-fluoropyridin-3-yl)methyl]-N-[(1S,2S)-2-hydroxycyclohexyl]-1-methyl-2,3-dihydropyrrolo[2,3-b]pyridine-6-carboxamide Chemical compound O[C@@H]1[C@H](CCCC1)NC(=O)C1=CC(=C2C(=N1)N(CC2)C)CC=1C=CC(=NC=1)F FQZFWEZFMXFNLY-WMZOPIPTSA-N 0.000 claims 1
- UBLLDDULGIGADY-WMZOPIPTSA-N 4-[(6-fluoropyridin-3-yl)methyl]-N-[(1S,2S)-2-hydroxycyclohexyl]-1-methylpyrrolo[2,3-b]pyridine-6-carboxamide Chemical compound O[C@@H]1[C@H](CCCC1)NC(=O)C1=CC(=C2C(=N1)N(C=C2)C)CC=1C=CC(=NC=1)F UBLLDDULGIGADY-WMZOPIPTSA-N 0.000 claims 1
- BVPWCZRFQZXFCQ-LPHOPBHVSA-N 4-[(6-fluoropyridin-3-yl)methyl]-N-[(1S,2S)-2-hydroxycyclohexyl]-5,6,7,8-tetrahydro-1,7-naphthyridine-2-carboxamide Chemical compound O[C@H]1CCCC[C@@H]1NC(=O)C1=CC(CC2=CN=C(F)C=C2)=C2CCNCC2=N1 BVPWCZRFQZXFCQ-LPHOPBHVSA-N 0.000 claims 1
- FHMILXMRRXJPQK-QSVLQNJRSA-N 4-[(6-fluoropyridin-3-yl)methyl]-N-[(1S,2S)-2-hydroxycyclohexyl]-5,6,7,8-tetrahydro-1,7-naphthyridine-2-carboxamide hydrochloride Chemical compound Cl.O[C@@H]1[C@H](CCCC1)NC(=O)C1=NC=2CNCCC2C(=C1)CC=1C=CC(=NC1)F FHMILXMRRXJPQK-QSVLQNJRSA-N 0.000 claims 1
- FMGLNXVSGFSMKI-UPVQGACJSA-N 4-[[2-fluoro-4-(1-methylpyrazol-4-yl)phenyl]methyl]-N-[(1S,2S)-2-hydroxycyclohexyl]-1-methylpyrrolo[2,3-b]pyridine-6-carboxamide Chemical compound O[C@@H]1[C@H](CCCC1)NC(=O)C1=CC(=C2C(=N1)N(C=C2)C)CC1=C(C=C(C=C1)C=1C=NN(C=1)C)F FMGLNXVSGFSMKI-UPVQGACJSA-N 0.000 claims 1
- PTCPWOIUPBJSCY-GMAHTHKFSA-N 4-[[6-(6-fluoropyridin-3-yl)pyridin-3-yl]methyl]-N-[(1S,2S)-2-hydroxycyclohexyl]-1-methyl-2,3-dihydropyrrolo[2,3-b]pyridine-6-carboxamide Chemical compound O[C@@H]1[C@H](CCCC1)NC(=O)C1=CC(=C2C(=N1)N(CC2)C)CC=1C=CC(=NC=1)C=1C=CC(=NC=1)F PTCPWOIUPBJSCY-GMAHTHKFSA-N 0.000 claims 1
- GAJLZIVTIMKGMB-GMAHTHKFSA-N 4-[[6-(6-fluoropyridin-3-yl)pyridin-3-yl]methyl]-N-[(1S,2S)-2-hydroxycyclohexyl]-1-methylpyrrolo[2,3-b]pyridine-6-carboxamide Chemical compound O[C@@H]1[C@H](CCCC1)NC(=O)C1=CC(=C2C(=N1)N(C=C2)C)CC=1C=CC(=NC=1)C=1C=CC(=NC=1)F GAJLZIVTIMKGMB-GMAHTHKFSA-N 0.000 claims 1
- HMCNKJBJCLDZRV-PXNSSMCTSA-N 7-[(4-fluorophenyl)methyl]-N-[(1S,2S)-2-hydroxycyclohexyl]-1-methylpyrrolo[3,2-b]pyridine-5-carboxamide Chemical compound O[C@@H]1[C@H](CCCC1)NC(=O)C1=CC(=C2C(=N1)C=CN2C)CC1=CC=C(C=C1)F HMCNKJBJCLDZRV-PXNSSMCTSA-N 0.000 claims 1
- JTJYPPALJLHMKU-OALUTQOASA-N 7-[(4-fluorophenyl)methyl]-N-[(3S,4S)-4-hydroxyoxan-3-yl]-1-methylpyrrolo[3,2-b]pyridine-5-carboxamide Chemical compound O[C@@H]1[C@H](COCC1)NC(=O)C1=CC(=C2C(=N1)C=CN2C)CC1=CC=C(C=C1)F JTJYPPALJLHMKU-OALUTQOASA-N 0.000 claims 1
- HWJYBQQYEOLHOU-YJBOKZPZSA-N 7-[(6-chloropyridin-3-yl)methyl]-N-[(1S,2S)-2-hydroxycyclohexyl]-1-methylpyrrolo[3,2-b]pyridine-5-carboxamide Chemical compound O[C@@H]1[C@H](CCCC1)NC(=O)C1=CC(=C2C(=N1)C=CN2C)CC=1C=CC(=NC=1)Cl HWJYBQQYEOLHOU-YJBOKZPZSA-N 0.000 claims 1
- MDNHIZMIQXNXGV-REWPJTCUSA-N 7-ethyl-4-[(4-fluorophenyl)methyl]-N-[(1S,2S)-2-hydroxycyclohexyl]-6,8-dihydro-5H-1,7-naphthyridine-2-carboxamide Chemical compound CCN1CCC2=C(CC3=CC=C(F)C=C3)C=C(N=C2C1)C(=O)N[C@H]1CCCC[C@@H]1O MDNHIZMIQXNXGV-REWPJTCUSA-N 0.000 claims 1
- PIIJVCLVNICFHF-HKUYNNGSSA-N 8-[(4-fluorophenyl)methyl]-N-[(1S,2S)-2-hydroxycyclohexyl]-4-methyl-2,3-dihydropyrido[3,2-b][1,4]oxazine-6-carboxamide Chemical compound O[C@@H]1[C@H](CCCC1)NC(=O)C=1C=C(C=2OCCN(C=2N=1)C)CC1=CC=C(C=C1)F PIIJVCLVNICFHF-HKUYNNGSSA-N 0.000 claims 1
- YAMLINZVYVTQIZ-IRXDYDNUSA-N 8-[(4-fluorophenyl)methyl]-N-[(3S,4S)-4-hydroxyoxan-3-yl]-2,3-dihydro-[1,4]dioxino[2,3-b]pyridine-6-carboxamide Chemical compound O[C@@H]1[C@H](COCC1)NC(=O)C1=CC(=C2C(=N1)OCCO2)CC1=CC=C(C=C1)F YAMLINZVYVTQIZ-IRXDYDNUSA-N 0.000 claims 1
- OIXZBUQGHRDKQE-ROUUACIJSA-N 8-[(4-fluorophenyl)methyl]-N-[(3S,4S)-4-hydroxyoxan-3-yl]-4-methyl-2,3-dihydropyrido[3,2-b][1,4]oxazine-6-carboxamide Chemical compound CN1CCOc2c(Cc3ccc(F)cc3)cc(nc12)C(=O)N[C@H]1COCC[C@@H]1O OIXZBUQGHRDKQE-ROUUACIJSA-N 0.000 claims 1
- VJEAPPJNQVZIAU-GJZGRUSLSA-N 8-[(6-chloropyridin-3-yl)methyl]-N-[(3S,4S)-4-hydroxyoxan-3-yl]-2,3-dihydro-[1,4]dioxino[2,3-b]pyridine-6-carboxamide Chemical compound O[C@@H]1[C@H](COCC1)NC(=O)C1=CC(=C2C(=N1)OCCO2)CC=1C=CC(=NC=1)Cl VJEAPPJNQVZIAU-GJZGRUSLSA-N 0.000 claims 1
- SATFXGWWEZDPNI-RDJZCZTQSA-N CN1CCOC2=C(CC3=CC(F)=NC=C3)C=C(N=C12)C(=O)N[C@H]1CCCC[C@@H]1O Chemical compound CN1CCOC2=C(CC3=CC(F)=NC=C3)C=C(N=C12)C(=O)N[C@H]1CCCC[C@@H]1O SATFXGWWEZDPNI-RDJZCZTQSA-N 0.000 claims 1
- IZNLOZFDJYWBOT-HKUYNNGSSA-N CN1CCOC2=C(CC3=CN=C(C)C=C3)C=C(N=C12)C(=O)N[C@H]1CCCC[C@@H]1O Chemical compound CN1CCOC2=C(CC3=CN=C(C)C=C3)C=C(N=C12)C(=O)N[C@H]1CCCC[C@@H]1O IZNLOZFDJYWBOT-HKUYNNGSSA-N 0.000 claims 1
- YVJUYGLZJROASR-RDJZCZTQSA-N CN1CCOC2=C(CC3=CN=C(Cl)C=C3)C=C(N=C12)C(=O)N[C@H]1CCCC[C@@H]1O Chemical compound CN1CCOC2=C(CC3=CN=C(Cl)C=C3)C=C(N=C12)C(=O)N[C@H]1CCCC[C@@H]1O YVJUYGLZJROASR-RDJZCZTQSA-N 0.000 claims 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims 1
- 201000010374 Down Syndrome Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000009829 Lewy Body Disease Diseases 0.000 claims 1
- 201000002832 Lewy body dementia Diseases 0.000 claims 1
- GGRCAZZCOBXTOT-UHFFFAOYSA-N N-(2-hydroxy-2-methylpropyl)-1-methyl-4-[[4-(1,3-thiazol-4-yl)phenyl]methyl]pyrrolo[2,3-b]pyridine-6-carboxamide Chemical compound OC(CNC(=O)C1=CC(=C2C(=N1)N(C=C2)C)CC1=CC=C(C=C1)C=1N=CSC=1)(C)C GGRCAZZCOBXTOT-UHFFFAOYSA-N 0.000 claims 1
- GOOVJKONIWHGGY-UHFFFAOYSA-N N-[(1-hydroxycyclopentyl)methyl]-1-methyl-4-[[4-(1,3-thiazol-4-yl)phenyl]methyl]pyrrolo[2,3-b]pyridine-6-carboxamide Chemical compound OC1(CCCC1)CNC(=O)C1=CC(=C2C(=N1)N(C=C2)C)CC1=CC=C(C=C1)C=1N=CSC=1 GOOVJKONIWHGGY-UHFFFAOYSA-N 0.000 claims 1
- KOSGPHNCWZORLF-WSTRIDTPSA-N N-[(1S,2S)-2-hydroxycyclohexyl]-1-methyl-2-[(6-methylpyridin-3-yl)methyl]-2,3-dihydropyrrolo[2,3-b]pyridine-6-carboxamide Chemical compound O[C@@H]1[C@H](CCCC1)NC(=O)C1=CC=C2C(=N1)N(C(C2)CC=1C=NC(=CC=1)C)C KOSGPHNCWZORLF-WSTRIDTPSA-N 0.000 claims 1
- ASHFCWSHKYLJEJ-HKUYNNGSSA-N N-[(1S,2S)-2-hydroxycyclohexyl]-1-methyl-4-(pyridin-3-ylmethyl)pyrrolo[2,3-b]pyridine-6-carboxamide Chemical compound O[C@@H]1[C@H](CCCC1)NC(=O)C1=CC(=C2C(=N1)N(C=C2)C)CC=1C=NC=CC=1 ASHFCWSHKYLJEJ-HKUYNNGSSA-N 0.000 claims 1
- MQQIZXJTKZFQLD-HKUYNNGSSA-N N-[(1S,2S)-2-hydroxycyclohexyl]-1-methyl-4-(pyridin-4-ylmethyl)pyrrolo[2,3-b]pyridine-6-carboxamide Chemical compound O[C@@H]1[C@H](CCCC1)NC(=O)C1=CC(=C2C(=N1)N(C=C2)C)CC1=CC=NC=C1 MQQIZXJTKZFQLD-HKUYNNGSSA-N 0.000 claims 1
- VJJBZWIDWHWMCQ-RXVVDRJESA-N N-[(1S,2S)-2-hydroxycyclohexyl]-1-methyl-4-[(1-methylbenzimidazol-4-yl)methyl]pyrrolo[2,3-b]pyridine-6-carboxamide Chemical compound O[C@@H]1[C@H](CCCC1)NC(=O)C1=CC(=C2C(=N1)N(C=C2)C)CC1=CC=CC=2N(C=NC=21)C VJJBZWIDWHWMCQ-RXVVDRJESA-N 0.000 claims 1
- LUSCZTROPZQUGC-ICSRJNTNSA-N N-[(1S,2S)-2-hydroxycyclohexyl]-1-methyl-4-[(2-methylpyridin-4-yl)methyl]-2,3-dihydropyrrolo[2,3-b]pyridine-6-carboxamide Chemical compound O[C@@H]1[C@H](CCCC1)NC(=O)C1=CC(=C2C(=N1)N(CC2)C)CC1=CC(=NC=C1)C LUSCZTROPZQUGC-ICSRJNTNSA-N 0.000 claims 1
- ZXQDYIAVUDDWSS-ICSRJNTNSA-N N-[(1S,2S)-2-hydroxycyclohexyl]-1-methyl-4-[(2-methylpyridin-4-yl)methyl]pyrrolo[2,3-b]pyridine-6-carboxamide Chemical compound O[C@@H]1[C@H](CCCC1)NC(=O)C1=CC(=C2C(=N1)N(C=C2)C)CC1=CC(=NC=C1)C ZXQDYIAVUDDWSS-ICSRJNTNSA-N 0.000 claims 1
- FDKVEIBYMHHWHX-GMAHTHKFSA-N N-[(1S,2S)-2-hydroxycyclohexyl]-1-methyl-4-[(4-pyrazol-1-ylphenyl)methyl]pyrrolo[2,3-b]pyridine-6-carboxamide Chemical compound O[C@@H]1[C@H](CCCC1)NC(=O)C1=CC(=C2C(=N1)N(C=C2)C)CC1=CC=C(C=C1)N1N=CC=C1 FDKVEIBYMHHWHX-GMAHTHKFSA-N 0.000 claims 1
- NRMRASHMQACCGL-ICSRJNTNSA-N N-[(1S,2S)-2-hydroxycyclohexyl]-1-methyl-4-[(6-methylpyridin-3-yl)methyl]pyrrolo[2,3-b]pyridine-6-carboxamide Chemical compound O[C@@H]1[C@H](CCCC1)NC(=O)C1=CC(=C2C(=N1)N(C=C2)C)CC=1C=CC(=NC=1)C NRMRASHMQACCGL-ICSRJNTNSA-N 0.000 claims 1
- LBJGRIRFLSHQLI-HKUYNNGSSA-N N-[(1S,2S)-2-hydroxycyclohexyl]-1-methyl-4-[(6-methylsulfanylpyridin-3-yl)methyl]pyrrolo[2,3-b]pyridine-6-carboxamide Chemical compound O[C@@H]1[C@H](CCCC1)NC(=O)C1=CC(=C2C(=N1)N(C=C2)C)CC=1C=CC(=NC=1)SC LBJGRIRFLSHQLI-HKUYNNGSSA-N 0.000 claims 1
- VYIKKWYVRLFQLD-REWPJTCUSA-N N-[(1S,2S)-2-hydroxycyclohexyl]-1-methyl-4-[[4-(1,3-thiazol-4-yl)phenyl]methyl]pyrrolo[2,3-b]pyridine-6-carboxamide Chemical compound O[C@@H]1[C@H](CCCC1)NC(=O)C1=CC(=C2C(=N1)N(C=C2)C)CC1=CC=C(C=C1)C=1N=CSC=1 VYIKKWYVRLFQLD-REWPJTCUSA-N 0.000 claims 1
- ONRZHTWYMXXQPV-UPVQGACJSA-N N-[(1S,2S)-2-hydroxycyclohexyl]-1-methyl-4-[[4-(1-methylpyrazol-4-yl)phenyl]methyl]pyrrolo[2,3-b]pyridine-6-carboxamide Chemical compound O[C@@H]1[C@H](CCCC1)NC(=O)C1=CC(=C2C(=N1)N(C=C2)C)CC1=CC=C(C=C1)C=1C=NN(C=1)C ONRZHTWYMXXQPV-UPVQGACJSA-N 0.000 claims 1
- NHZWXUYGSYPBQR-AHWVRZQESA-N N-[(1S,2S)-2-hydroxycyclohexyl]-1-methyl-4-[[4-(2-methylpyridin-3-yl)phenyl]methyl]pyrrolo[2,3-b]pyridine-6-carboxamide Chemical compound O[C@@H]1[C@H](CCCC1)NC(=O)C1=CC(=C2C(=N1)N(C=C2)C)CC1=CC=C(C=C1)C=1C(=NC=CC=1)C NHZWXUYGSYPBQR-AHWVRZQESA-N 0.000 claims 1
- QETXCVVDKIZVFR-GMAHTHKFSA-N N-[(1S,2S)-2-hydroxycyclohexyl]-1-methyl-4-[[6-(1-methylpyrazol-4-yl)pyridin-3-yl]methyl]pyrrolo[2,3-b]pyridine-6-carboxamide Chemical compound O[C@@H]1[C@H](CCCC1)NC(=O)C1=CC(=C2C(=N1)N(C=C2)C)CC=1C=CC(=NC=1)C=1C=NN(C=1)C QETXCVVDKIZVFR-GMAHTHKFSA-N 0.000 claims 1
- JVFYFDFPYAWGPD-FPOVZHCZSA-N N-[(1S,2S)-2-hydroxycyclohexyl]-4-[(4-methoxyphenyl)methyl]-1-methyl-2,3-dihydropyrrolo[2,3-b]pyridine-6-carboxamide Chemical compound O[C@@H]1[C@H](CCCC1)NC(=O)C1=CC(=C2C(=N1)N(CC2)C)CC1=CC=C(C=C1)OC JVFYFDFPYAWGPD-FPOVZHCZSA-N 0.000 claims 1
- ACYWAPQRSDKWHF-FPOVZHCZSA-N N-[(1S,2S)-2-hydroxycyclohexyl]-4-[(4-methoxyphenyl)methyl]-1-methylpyrrolo[2,3-b]pyridine-6-carboxamide Chemical compound O[C@@H]1[C@H](CCCC1)NC(=O)C1=CC(=C2C(=N1)N(C=C2)C)CC1=CC=C(C=C1)OC ACYWAPQRSDKWHF-FPOVZHCZSA-N 0.000 claims 1
- WVWJJRSVKHMUFA-UGKGYDQZSA-N N-[(1S,2S)-2-hydroxycyclohexyl]-4-[(4-methoxyphenyl)methyl]-5,6,7,8-tetrahydro-1,7-naphthyridine-2-carboxamide Chemical compound COC1=CC=C(CC2=C3CCNCC3=NC(=C2)C(=O)N[C@H]2CCCC[C@@H]2O)C=C1 WVWJJRSVKHMUFA-UGKGYDQZSA-N 0.000 claims 1
- HFLKJUADIJQDDA-CQERKEQDSA-N N-[(1S,2S)-2-hydroxycyclohexyl]-4-[(4-methoxyphenyl)methyl]-5,6,7,8-tetrahydro-1,7-naphthyridine-2-carboxamide hydrochloride Chemical compound Cl.O[C@@H]1[C@H](CCCC1)NC(=O)C1=NC=2CNCCC2C(=C1)CC1=CC=C(C=C1)OC HFLKJUADIJQDDA-CQERKEQDSA-N 0.000 claims 1
- FADKULFJDLLCEL-URXFXBBRSA-N N-[(1S,2S)-2-hydroxycyclohexyl]-4-[(4-pyrazol-1-ylphenyl)methyl]-5,6,7,8-tetrahydro-1,7-naphthyridine-2-carboxamide Chemical compound O[C@H]1CCCC[C@@H]1NC(=O)C1=CC(CC2=CC=C(C=C2)N2C=CC=N2)=C2CCNCC2=N1 FADKULFJDLLCEL-URXFXBBRSA-N 0.000 claims 1
- BCVUNEKOFYAZKH-TUYUPMGOSA-N N-[(1S,2S)-2-hydroxycyclohexyl]-4-[(4-pyrazol-1-ylphenyl)methyl]-5,6,7,8-tetrahydro-1,7-naphthyridine-2-carboxamide hydrochloride Chemical compound Cl.O[C@@H]1[C@H](CCCC1)NC(=O)C1=NC=2CNCCC2C(=C1)CC1=CC=C(C=C1)N1N=CC=C1 BCVUNEKOFYAZKH-TUYUPMGOSA-N 0.000 claims 1
- IDBUFNGLYZOUFM-HKUYNNGSSA-N N-[(1S,2S)-2-hydroxycyclohexyl]-4-[(6-methoxypyridin-3-yl)methyl]-1-methylpyrrolo[2,3-b]pyridine-6-carboxamide Chemical compound O[C@@H]1[C@H](CCCC1)NC(=O)C1=CC(=C2C(=N1)N(C=C2)C)CC=1C=CC(=NC=1)OC IDBUFNGLYZOUFM-HKUYNNGSSA-N 0.000 claims 1
- WZXGJVJIGLVVKE-DHLKQENFSA-N N-[(1S,2S)-2-hydroxycyclohexyl]-4-[[4-(1-methylpyrazol-4-yl)phenyl]methyl]-5,6,7,8-tetrahydro-1,7-naphthyridine-2-carboxamide Chemical compound CN1C=C(C=N1)C1=CC=C(CC2=C3CCNCC3=NC(=C2)C(=O)N[C@H]2CCCC[C@@H]2O)C=C1 WZXGJVJIGLVVKE-DHLKQENFSA-N 0.000 claims 1
- XUBYHOFOLYWHCP-YSCHMLPRSA-N N-[(1S,2S)-2-hydroxycyclohexyl]-4-[[4-(1-methylpyrazol-4-yl)phenyl]methyl]-5,6,7,8-tetrahydro-1,7-naphthyridine-2-carboxamide hydrochloride Chemical compound Cl.O[C@@H]1[C@H](CCCC1)NC(=O)C1=NC=2CNCCC2C(=C1)CC1=CC=C(C=C1)C=1C=NN(C1)C XUBYHOFOLYWHCP-YSCHMLPRSA-N 0.000 claims 1
- QXGGBOIRFDKPRC-RDJZCZTQSA-N N-[(1S,2S)-2-hydroxycyclohexyl]-4-methyl-8-[(1-methylpyrazol-4-yl)methyl]-2,3-dihydropyrido[3,2-b][1,4]oxazine-6-carboxamide Chemical compound O[C@@H]1[C@H](CCCC1)NC(=O)C=1C=C(C=2OCCN(C=2N=1)C)CC=1C=NN(C=1)C QXGGBOIRFDKPRC-RDJZCZTQSA-N 0.000 claims 1
- XZDQVMIXAFRBBZ-UNMCSNQZSA-N N-[(1S,2S)-2-hydroxycyclohexyl]-4-methyl-8-[(4-pyrazol-1-ylphenyl)methyl]-2,3-dihydropyrido[3,2-b][1,4]oxazine-6-carboxamide Chemical compound O[C@@H]1[C@H](CCCC1)NC(=O)C=1C=C(C=2OCCN(C=2N=1)C)CC1=CC=C(C=C1)N1N=CC=C1 XZDQVMIXAFRBBZ-UNMCSNQZSA-N 0.000 claims 1
- BUPLOUQZUVXQSM-HOCLYGCPSA-N N-[(1S,2S)-2-hydroxycyclohexyl]-8-[(1-methylpyrazol-4-yl)methyl]-2,3-dihydro-[1,4]dioxino[2,3-b]pyridine-6-carboxamide Chemical compound O[C@@H]1[C@H](CCCC1)NC(=O)C1=CC(=C2C(=N1)OCCO2)CC=1C=NN(C=1)C BUPLOUQZUVXQSM-HOCLYGCPSA-N 0.000 claims 1
- FKUBQXRZINZOCN-UNMCSNQZSA-N N-[(1S,2S)-2-hydroxycyclohexyl]-8-[[4-(1-methylpyrazol-4-yl)phenyl]methyl]-2,3-dihydro-[1,4]dioxino[2,3-b]pyridine-6-carboxamide Chemical compound Cn1cc(cn1)-c1ccc(Cc2cc(nc3OCCOc23)C(=O)N[C@H]2CCCC[C@@H]2O)cc1 FKUBQXRZINZOCN-UNMCSNQZSA-N 0.000 claims 1
- YMZKOYORHSWFKE-OALUTQOASA-N N-[(3S,4S)-4-hydroxyoxan-3-yl]-1-methyl-4-[(6-methylpyridin-3-yl)methyl]-2,3-dihydropyrrolo[2,3-b]pyridine-6-carboxamide Chemical compound O[C@@H]1[C@H](COCC1)NC(=O)C1=CC(=C2C(=N1)N(CC2)C)CC=1C=CC(=NC=1)C YMZKOYORHSWFKE-OALUTQOASA-N 0.000 claims 1
- MXMSQEZQGXLQEC-OALUTQOASA-N N-[(3S,4S)-4-hydroxyoxan-3-yl]-1-methyl-4-[(6-methylpyridin-3-yl)methyl]pyrrolo[2,3-b]pyridine-6-carboxamide Chemical compound CN1C=CC2=C1N=C(C=C2CC1=CN=C(C)C=C1)C(=O)N[C@H]1COCC[C@@H]1O MXMSQEZQGXLQEC-OALUTQOASA-N 0.000 claims 1
- REZDYEHXEJBAMU-PMACEKPBSA-N N-[(3S,4S)-4-hydroxyoxan-3-yl]-4-[(4-methoxyphenyl)methyl]-1-methyl-2,3-dihydropyrrolo[2,3-b]pyridine-6-carboxamide Chemical compound O[C@@H]1[C@H](COCC1)NC(=O)C1=CC(=C2C(=N1)N(CC2)C)CC1=CC=C(C=C1)OC REZDYEHXEJBAMU-PMACEKPBSA-N 0.000 claims 1
- HPSMVSQUFDRDLH-PMACEKPBSA-N N-[(3S,4S)-4-hydroxyoxan-3-yl]-4-[(4-methoxyphenyl)methyl]-1-methylpyrrolo[2,3-b]pyridine-6-carboxamide Chemical compound COC1=CC=C(CC2=CC(=NC3=C2C=CN3C)C(=O)N[C@H]2COCC[C@@H]2O)C=C1 HPSMVSQUFDRDLH-PMACEKPBSA-N 0.000 claims 1
- WGJLKEXXMCHYEK-PMACEKPBSA-N N-[(3S,4S)-4-hydroxyoxan-3-yl]-7-[(4-methoxyphenyl)methyl]-1-methylpyrrolo[3,2-b]pyridine-5-carboxamide Chemical compound O[C@@H]1[C@H](COCC1)NC(=O)C1=CC(=C2C(=N1)C=CN2C)CC1=CC=C(C=C1)OC WGJLKEXXMCHYEK-PMACEKPBSA-N 0.000 claims 1
- UMYLPSPKSLWLLW-IRXDYDNUSA-N N-[(3S,4S)-4-hydroxyoxan-3-yl]-8-[(6-methylpyridin-3-yl)methyl]-2,3-dihydro-[1,4]dioxino[2,3-b]pyridine-6-carboxamide Chemical compound O[C@@H]1[C@H](COCC1)NC(=O)C1=CC(=C2C(=N1)OCCO2)CC=1C=CC(=NC=1)C UMYLPSPKSLWLLW-IRXDYDNUSA-N 0.000 claims 1
- 229940127523 NMDA Receptor Antagonists Drugs 0.000 claims 1
- SUHRDXCTHDQCJT-HKUYNNGSSA-N O[C@@H]1[C@H](CCCC1)NC(=O)C=1C=C(C=2OCCN(C=2N=1)C)CC1=CC(=CC=C1)F Chemical compound O[C@@H]1[C@H](CCCC1)NC(=O)C=1C=C(C=2OCCN(C=2N=1)C)CC1=CC(=CC=C1)F SUHRDXCTHDQCJT-HKUYNNGSSA-N 0.000 claims 1
- JMAQRDRNKQNKFR-GMAHTHKFSA-N O[C@@H]1[C@H](CCCC1)NC(=O)C=1C=C(C=2OCCN(C=2N=1)C)CC1=CC=C(C=C1)C=1C=NN(C=1)C Chemical compound O[C@@H]1[C@H](CCCC1)NC(=O)C=1C=C(C=2OCCN(C=2N=1)C)CC1=CC=C(C=C1)C=1C=NN(C=1)C JMAQRDRNKQNKFR-GMAHTHKFSA-N 0.000 claims 1
- LCDLTNSONXRWEF-ICSRJNTNSA-N O[C@@H]1[C@H](CCCC1)NC(=O)C=1C=C(C=2OCCN(C=2N=1)C)CC1=CC=C(C=C1)OC Chemical compound O[C@@H]1[C@H](CCCC1)NC(=O)C=1C=C(C=2OCCN(C=2N=1)C)CC1=CC=C(C=C1)OC LCDLTNSONXRWEF-ICSRJNTNSA-N 0.000 claims 1
- HRTMUACOZJRINE-SFTDATJTSA-N O[C@@H]1[C@H](COCC1)NC(=O)C=1C=C(C=2OCCN(C=2N=1)C)CC1=CC=C(C=C1)N1N=CC=C1 Chemical compound O[C@@H]1[C@H](COCC1)NC(=O)C=1C=C(C=2OCCN(C=2N=1)C)CC1=CC=C(C=C1)N1N=CC=C1 HRTMUACOZJRINE-SFTDATJTSA-N 0.000 claims 1
- FAJAUSLJVFWEAQ-OALUTQOASA-N O[C@@H]1[C@H](COCC1)NC(=O)C=1C=C(C=2OCCN(C=2N=1)C)CC1=CC=C(C=C1)OC Chemical compound O[C@@H]1[C@H](COCC1)NC(=O)C=1C=C(C=2OCCN(C=2N=1)C)CC1=CC=C(C=C1)OC FAJAUSLJVFWEAQ-OALUTQOASA-N 0.000 claims 1
- UQXGDWCZDCWRTN-HOTGVXAUSA-N O[C@@H]1[C@H](COCC1)NC(=O)C=1C=C(C=2OCCN(C=2N=1)C)CC=1C=NN(C=1)C Chemical compound O[C@@H]1[C@H](COCC1)NC(=O)C=1C=C(C=2OCCN(C=2N=1)C)CC=1C=NN(C=1)C UQXGDWCZDCWRTN-HOTGVXAUSA-N 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims 1
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 claims 1
- 206010039966 Senile dementia Diseases 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 208000016620 Tourette disease Diseases 0.000 claims 1
- 206010044688 Trisomy 21 Diseases 0.000 claims 1
- 201000004810 Vascular dementia Diseases 0.000 claims 1
- 239000000544 cholinesterase inhibitor Substances 0.000 claims 1
- 229960003530 donepezil Drugs 0.000 claims 1
- 229960003980 galantamine Drugs 0.000 claims 1
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 claims 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 claims 1
- 229960004640 memantine Drugs 0.000 claims 1
- 230000002085 persistent effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229960004136 rivastigmine Drugs 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 229960001685 tacrine Drugs 0.000 claims 1
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Claims (11)
1. Spoj formule (I),
[image]
naznačen time što:
prsten A je odabran od:
[image]
[image]
[image]
[image]
A1 je CH2, CHF ili CF2;
R1 je odabran iz grupe koja se sastoji od:
[image]
Ra je OH;
X1 je neovisno odabran od CH2 ili O;
a je 0 ili 1;
R2 je -(C6-10)-aril ili -(C5-10)-heteroaril; od kojih je svaki izborno supstituiran sa jednim ili više supstituenata odabranih od halogena, -O-(C1-4)-alkila, -S-(C1-4)-alkila, -N(CH3)2, -(C1-4)-alkila, -(C3-6)-cikloalkila, halo(C1-4)-alkila, -OH, -NH2, -CN ili R2a;
R2a je -(C6-10)-aril ili (C5-10)-heteroaril; od kojih je svaki izborno supstituiran sa jednim ili više supstituenata odabranih iz grupe koja se sastoji od halogena, -OH, -NH2, -CN, -O-(C1-2)-alkila, -S-(C1-2)-alkila, -(C1-2)-alkila ili (C3-6)-cikloalkila;
R3 je -(C1-4)-alkil, -(C3-6)-cikloalkil, -(C1-4)-alkil-(C3-6)-cikloalkil, halo(C1-4)-alkil i vodik; i
R4 je vodik, -(C1-4)-alkil i halo(C1-4)-alkil;
ili izotopski oblik, stereoizomer, tautomer ili njihova farmaceutski prihvatljiva sol.
2. Spoj formule (I) prema patentnom zahtjevu 1, naznačen time što:
R2 je odabran iz grupe koja se sastoji od:
[image]
A3 je N ili CH;
A4 je CH ili CF;
Rb u svakom pojavljivanju je neovisno odabran od halogena, -O-(C1-4)-alkila, -S-(C1-4)-alkila, -N(CH3)2, -(C1-4)-alkila, -(C3-6)-cikloalkila, halo(C1-4)-alkila, -OH, -NH2, -CN, fenila, piridila, pirazolila, tiazolila i oksazolila; pri čemu su fenil, piridil, pirazolil, tiazolil i oksazolil izborno supstituirani sa jednim ili više supstituenata odabranih iz grupe koja se sastoji od halogena, -OH, -NH2, -CN, -O- (C1-2)-alkila, -S-(C1-2)-alkila, -(C1-2)-alkila ili -(C3-6)-cikloalkila;
Rc je vodik ili -(C1-4)-alkil;
X2 je neovisno odabran od NH, -N-(C1-2)-alkila, O ili S;
X3 je neovisno odabran od CH ili N;
b je 0, 1 ili 2;
"
[image]
" predstavlja točku vezanosti.
3. Spoj formule (I) prema patentnom zahtjevu 1, naznačen time što:
prsten A je odabran od,
[image]
[image]
[image]
A1 je CH2;
R2 je odabran iz grupe koja se sastoji od:
[image]
A3 je N ili CH;
A4 je CH ili CF;
Rb u svakom pojavljivanju je neovisno odabran od halogena, -O-(C1-4)-alkila, -S-(C1-4)-alkila, -N(CH3)2, -(C1-4)-alkila, -(C3-6)-cikloalkila, halo(C1-4)-alkila, -OH, -NH2, -CN, fenila, piridila, pirazolila, tiazolila i oksazolila; pri čemu su fenil, piridil, pirazolil, tiazolil i oksazolil izborno supstituirani sa jednim ili više supstituenata odabranih iz grupe koja se sastoji od halogena, -OH, -NH2, -CN, -O- (C1-2)-alkila, -S-(C1-2)-alkila, -(C1-2)-alkila ili -(C3-6)-cikloalkila;
Rc je vodik ili -(C1-4)-alkil;
X2 je neovisno odabran od NH, -N-(C1-2)-alkila, O ili S;
X3 je neovisno odabran od CH ili N;
b je 0, 1 ili 2;
"
[image]
" predstavlja točku vezanosti;
R3 je -(C1-4)-alkil, halo(C1-4)-alkil ili vodik; i
R4 je vodik, -(C1-4)-alkil i halo(C1-4)-alkil;
ili izotopski oblik, stereoizomer, tautomer ili njihova farmaceutski prihvatljiva sol.
4. Spoj prema bilo kojem od patentnih zahtjeva 1 do 3, naznačen time što je spoj odabran iz grupe koja se sastoji od:
N-[(1S,2S)-2-hidroksicikloheksil]-4-(2-fluoropiridin-4-ilmetil)-1-metil-1H-pirolo[2,3-b]piridin-6-karboksamida;
N-[(1S,2S)-2-hidroksicikloheksil]-4-(2-metoksipiridin-5-ilmetil)-1-metil-1H-pirolo[2,3-b]piridin-6-karboksamida;
N-[(1S,2S)-2-hidroksicikloheksil]-4-(2-fluoropiridin-5-ilmetil)-1-metil-1H-pirolo[2,3-b]piridin-6-karboksamida;
N-[(1S,2S)-2-hidroksicikloheksil]-4-(4-fluorobenzil)-1-metil-1H-pirolo[2,3-b]piridin-6-karboksamida;
N-[(1S,2S)-2-hidroksicikloheksil]-4-(4-tiazol-4-ilbenzil)-1-metil-1H-pirolo[2,3-b]piridin-6-karboksamida;
N-[(1S,2S)-2-hidroksicikloheksil]-4-(4-pirazol-1-ilbenzil)-1-metil-1H-pirolo[2,3-b]piridin-6-karboksamida;
N-[(1S,2S)-2-hidroksicikloheksil]-4-[4-(1-metil-1H-pirazol-4-il)benzil]-1-metil-1H-pirolo[2,3-b]piridin-6-karboksamida;
N-[(1S,2S)-2-hidroksicikloheksil]-4-[2-fluoro-4-(1-metil-1H-pirazol-4-il)benzil]-1-metil-1H-pirolo[2,3-b]piridin-6-karboksamida;
N-[(1S,2S)-2-hidroksicikloheksil]-4-(2-metilpiridin-5-ilmetil)-1-metil-1H-pirolo[2,3-b]piridin-6-karboksamida;
N-[(1S,2S)-2-hidroksicikloheksil]-4-(2-kloropiridin-4-ilmetil)-1-metil-1H-pirolo[2,3-b]piridin-6-karboksamida;
N-[(1S,2S)-2-hidroksicikloheksil]-4-(2,5-difluoropiridin-4-ilmetil)-1-metil-1H-pirolo[2,3-b]piridin-6-karboksamida;
N-[(1S,2S)-2-hidroksicikloheksil]-4-(benzotiazol-6-ilmetil)-1-metil-1H-pirolo[2,3-b]piridin-6-karboksamida;
N-[(1S,2S)-2-hidroksicikloheksil]-4-(2’-fluoro-[2,5]bipiridinil-5-ilmetil)-1-metil-1H-pirolo[2,3-b]piridin-6-karboksamida;
N-[(1S,2S)-2-hidroksicikloheksil]-4-(piridin-4-ilmetil)-1-metil-1H-pirolo[2,3-b]piridin-6-karboksamida;
N-[(1S,2S)-2-hidroksicikloheksil]-4-[2-(1-metil-1H-pirazol-4-il)piridin-5-ilmetil]-1-metil-1H-pirolo[2,3-b]piridin-6-karboksamida;
N-[(1S,2S)-2-hidroksicikloheksil]-4-(2,3-difluorobenzil)-1-metil-1H-pirolo[2,3-b]piridin-6-karboksamida;
N-[(1S,2S)-2-hidroksicikloheksil]-4-(2-metilpiridin-4-ilmetil)-1-metil-1H-pirolo[2,3-b]piridin-6-karboksamida;
N-[(1S,2S)-2-hidroksicikloheksil]-4-(2-kloropiridin-5-ilmetil)-1-metil-1H-pirolo[2,3-b]piridin-6-karboksamida;
N-[(1S,2S)-2-hidroksicikloheksil]-4-(4-metoksibenzil)-1-metil-1H-pirolo[2,3-b]piridin-6-karboksamida;
N-[(1S,2S)-2-hidroksicikloheksil]-4-(2-metilsulfanilpiridin-5-ilmetil)-1-metil-1H-pirolo[2,3-b]piridin-6-karboksamida;
N-[(1S,2S)-2-hidroksicikloheksil]-4-[4-(2-metilpiridin-3-il)benzil]-1-metil-1H-pirolo[2,3-b]piridin-6-karboksamida;
N-[(1S,2S)-2-hidroksicikloheksil]-4-(1-metil-1H-benzimidazol-4-ilmetil)-1-metil-1H-pirolo[2,3-b]piridin-6-karboksamida;
N-[(1S,2S)-2-hidroksicikloheksil]-4-(2-kloropiridin-5-ilmetil)-1-(2-fluoroetil)-1H-pirolo[2,3-b]piridin-6-karboksamida;
N-(2-hidroksi-2-metilpropil)-4-[4-(tiazol-4-il)benzil]-1-metil-1H-pirolo[2,3-b]piridin-6-karboksamida;
N-[(1S,2S)-2-hidroksicikloheksil]-4-(3-fluorobenzil)-1-metil-1H-pirolo[2,3-b]piridin-6-karboksamida;
N-(1-hidroksiciklopentilmetil)-4-[4-(tiazol-4-il)benzil]-1-metil-1H-pirolo[2,3-b]piridin-6-karboksamida;
N-[(1S,2S)-2-hidroksicikloheksil]-4-(piridin-3-ilmetil)-1-metil-1H-pirolo[2,3-b]piridin-6-karboksamida;
N-[(1S,2S)-2-hidroksicikloheksil]-4-(2-ciklopropilpiridin-5-ilmetil)-1-metil-1H-pirolo[2,3-b]piridin-6-karboksamida;
N-[(1S,2S)-2-hidroksicikloheksil]-4-(2-fluoropiridin-4-ilmetil)-1-etil-1H-pirolo[2,3-b]piridin-6-karboksamida;
N-[(1S,2S)-2-hidroksicikloheksil]-4-(2-fluoropiridin-4-ilmetil)-1-izopropil-1H-pirolo[2,3-b]piridin-6-karboksamida;
N-[(1S,2S)-2-hidroksicikloheksil]-4-(2,3-difluorofenilmetil)-1,3-dimetil-1H-pirolo[2,3 -b]piridin-6-karboksamida;
Racemskog trans-N-(3-hidroksitetrahidropiran-4-il)-4-(4-fluorobenzil)-1-metil-1H-pirolo[2,3-b]piridin-6-karboksamida;
trans-N-(3-hidroksitetrahidropiran-4-il)-4-(4-fluorobenzil)-1-metil-1H-pirolo[2,3-b]piridin-6-karboksamida (Izomer-I);
trans-N-(3-hidroksitetrahidropiran-4-il)-4-(4-fluorobenzil)-1-metil-1H-pirolo[2,3-b]piridin-6-karboksamida (Izomer-II);
Racemskog cis-N-(3-hidroksitetrahidropiran-4-il)-4-(4-fluorobenzil)-1-metil-1H-pirolo[2,3-b]piridin-6-karboksamida;
cis-N-(3-hidroksitetrahidropiran-4-il)-4-(4-fluorobenzil)-1-metil-1H-pirolo[2,3-b]piridin-6-karboksamida (Izomer-I);
cis-N-(3-hidroksitetrahidropiran-4-il)-4-(4-fluorobenzil)-1-metil-1H-pirolo[2,3-b]piridin-6-karboksamida (Izomer-II);
Racemskog trans-N-(3-hidroksitetrahidropiran-4-il)-4-(2-fluoropiridin-4-ilmetil)-1-metil-1H-pirolo[2,3-b]piridin-6-karboksamida;
trans-N-(3-hidroksitetrahidropiran-4-il)-4-(2-fluoropiridin-4-ilmetil)-1-metil-1H-pirolo[2,3-b]piridin-6-karboksamida (Izomer-I);
trans-N-(3-hidroksitetrahidropiran-4-il)-4-(2-fluoropiridin-4-ilmetil)-1-metil-1H-pirolo[2,3-b]piridin-6-karboksamida (Izomer-II);
Racemskog cis-N-(3-hidroksitetrahidropiran-4-il)-4-(3,4-difluorobenzil)-1-metil-1H-pirolo[2,3-b]piridin-6-karboksamida;
cis-N-(3-hidroksitetrahidropiran-4-il)-4-(3,4-difluorobenzil)-1-metil-1H-pirolo[2,3-b]piridin-6-karboksamida (Izomer-I);
cis-N-(3-hidroksitetrahidropiran-4-il)-4-(3,4-difluorobenzil)-1-metil-1H-pirolo[2,3-b]piridin-6-karboksamida (Izomer-II);
Racemskog trans-N-(3-hidroksitetrahidropiran-4-il)-4-(2,3-difluorobenzil)-1-metil-1H-pirolo[2,3-b]piridin-6-karboksamida;
trans-N-(3-hidroksitetrahidropiran-4-il)-4-(2,3-difluorobenzil)-1-metil-1H-pirolo[2,3-b]piridin-6-karboksamida (Izomer-I);
trans-N-(3-hidroksitetrahidropiran-4-il)-4-(2,3-difluorobenzil)-1-metil-1H-pirolo[2,3-b]piridin-6-karboksamida (Izomer-II);
Racemskog cis-N-(3-hidroksitetrahidropiran-4-il)-4-(2,3-difluorobenzil)-1-metil-1H-pirolo[2,3-b]piridin-6-karboksamida;
cis-N-(3-hidroksitetrahidropiran-4-il)-4-(2,3-difluorobenzil)-1-metil-1H-pirolo[2,3-b]piridin-6-karboksamida (Izomer-I);
cis-N-(3-hidroksitetrahidropiran-4-il)-4-(2,3-difluorobenzil)-1-metil-1H-pirolo[2,3-b]piridin-6-karboksamida (Izomer-II);
Racemskog cis-N-(3-hidroksitetrahidropiran-4-il)-4-(2-fluoropiridin-4-ilmetil)-1-metil-1H-pirolo[2,3-b]piridin-6-karboksamida;
cis-N-(3-hidroksitetrahidropiran-4-il)-4-(2-fluoropiridin-4-ilmetil)-1-metil-1H-pirolo[2,3-b]piridin-6-karboksamida (Izomer-I);
cis-N-(3-hidroksitetrahidropiran-4-il)-4-(2-fluoropiridin-4-ilmetil)-1-metil-1H-pirolo[2,3-b]piridin-6-karboksamida (Izomer-II);
Racemskog cis-N-(3-hidroksitetrahidropiran-4-il)-4-(2-kloropiridin-5-ilmetil)-1-metil-1H-pirolo[2,3-b]piridin-6-karboksamida;
cis-N-(3-hidroksitetrahidropiran-4-il)-4-(2-kloropiridin-5-ilmetil)-1-metil-1H-pirolo[2,3-b]piridin-6-karboksamida (Izomer-I);
cis-N-(3-hidroksitetrahidropiran-4-il)-4-(2-kloropiridin-5-ilmetil)-1-metil-1H-pirolo[2,3-b]piridin-6-karboksamida (Izomer-II);
Racemskog trans-N-(3-hidroksitetrahidropiran-4-il)-4-(2-kloropiridin-5-ilmetil)-1-metil-1H-pirolo[2,3-b]piridin-6-karboksamida;
trans-N-(3-hidroksitetrahidropiran-4-il)-4-(2-kloropiridin-5-ilmetil)-1-metil-1H-pirolo[2,3-b]piridin-6-karboksamida (Izomer-I);
trans-N-(3-hidroksitetrahidropiran-4-il)-4-(2-kloropiridin-5-ilmetil)-1-metil-1H-pirolo[2,3-b]piridin-6-karboksamida (Izomer-II);
Racemskog trans-N-(3-hidroksitetrahidropiran-4-il)-4-(3,4-difluorobenzil)-1-metil-1H-pirolo[2,3-b]piridin-6-karboksamida;
trans-N-(3-hidroksitetrahidropiran-4-il)-4-(3,4-difluorobenzil)-1-metil-1H-pirolo[2,3-b]piridin-6-karboksamida (Izomer-I);
trans-N-(3-hidroksitetrahidropiran-4-il)-4-(3,4-difluorobenzil)-1-metil-1H-pirolo[2,3-b]piridin-6-karboksamida (Izomer-II);
Racemskog trans-N-(3-hidroksitetrahidropiran-4-il)-4-[4-(tiazol-4-il)benzil]-1-metil-1H-pirolo[2,3-b]piridin-6-karboksamida;
trans-N-(3-hidroksitetrahidropiran-4-il)-4-[4-(tiazol-4-il)benzil]-1-metil-1H-pirolo[2,3-b]piridin-6-karboksamida (Izomer-I);
trans-N-(3-hidroksitetrahidropiran-4-il)-4-[4-(tiazol-4-il)benzil]-1-metil-1H-pirolo[2,3-b]piridin-6-karboksamida (Izomer-II);
Racemskog cis-N-(3-hidroksitetrahidropiran-4-il)-4-[4-(tiazol-4-il)benzil]-1-metil-1H-pirolo[2,3-b]piridin-6-karboksamida;
cis-N-(3-hidroksitetrahidropiran-4-il)-4-[4-(tiazol-4-il)benzil]-1-metil-1H-pirolo[2,3-b]piridin-6-karboksamida (Izomer-I);
cis-N-(3-hidroksitetrahidropiran-4-il)-4-[4-(tiazol-4-il)benzil]-1-metil-1H-pirolo[2,3-b]piridin-6-karboksamida (Izomer-II);
Racemskog trans-N-(3-hidroksitetrahidropiran-4-il)-4-[4-(1-metil-1H-pirazol-4-il)benzil]-1-metil-1H-pirolo[2,3-b]piridin-6-karboksamida;
trans-N-(3-hidroksitetrahidropiran-4-il)-4-[4-(1-metil-1H-pirazol-4-il)benzil]-1-metil-1H-pirolo[2,3-b]piridin-6-karboksamida (Izomer-I);
trans-N-(3-hidroksitetrahidropiran-4-il)-4-[4-(1-metil-1H-pirazol-4-il)benzil]-1-metil-1H-pirolo[2,3-b]piridin-6-karboksamida (Izomer-II);
Racemskog cis-N-(3-hidroksitetrahidropiran-4-il)-4-[4-(1-metil-1H-pirazol-4-il)benzil]-1-metil-1H-pirolo[2,3-b]piridin-6-karboksamida;
cis-N-(3-hidroksitetrahidropiran-4-il)-4-[4-(1-metil-1H-pirazol-4-il)benzil]-1-metil-1H-pirolo[2,3-b]piridin-6-karboksamida (Izomer-I);
cis-N-(3-hidroksitetrahidropiran-4-il)-4-[4-(1-metil-1H-pirazol-4-il)benzil]-1-metil-1H-pirolo[2,3-b]piridin-6-karboksamida (Izomer-II);
Racemskog trans-N-(3-hidroksitetrahidropiran-4-il)-4-(4-metoksibenzil)-1-metil-1H-pirolo[2,3-b]piridin-6-karboksamida;
trans-N-(3-hidroksitetrahidropiran-4-il)-4-(4-metoksibenzil)-1-metil-1H-pirolo[2,3-b]piridin-6-karboksamida (Izomer-I);
trans-N-(3-hidroksitetrahidropiran-4-il)-4-(4-metoksibenzil)-1-metil-1H-pirolo[2,3-b]piridin-6-karboksamida (Izomer-II);
Racemskog cis-N-(3-hidroksitetrahidropiran-4-il)-4-(4-metoksibenzil)-1-metil-1H-pirolo[2,3-b]piridin-6-karboksamida;
cis-N-(3-hidroksitetrahidropiran-4-il)-4-(4-metoksibenzil)-1-metil-1H-pirolo[2,3-b]piridin-6-karboksamida (Izomer-I);
cis-N-(3-hidroksitetrahidropiran-4-il)-4-(4-metoksibenzil)-1-metil-1H-pirolo[2,3-b]piridin-6-karboksamida (Izomer-II);
Racemskog trans-N-(3-hidroksitetrahidropiran-4-il)-4-(3-fluorobenzil)-1-metil-1H-pirolo[2,3-b]piridin-6-karboksamida;
trans-N-(3-hidroksitetrahidropiran-4-il)-4-(3-fluorobenzil)-1-metil-1H-pirolo[2,3-b]piridin-6-karboksamida (Izomer-I);
trans-N-(3-hidroksitetrahidropiran-4-il)-4-(3-fluorobenzil)-1-metil-1H-pirolo[2,3-b]piridin-6-karboksamida (Izomer-II);
Racemskog cis-N-(3-hidroksitetrahidropiran-4-il)-4-(3-fluorobenzil)-1-metil-1H-pirolo[2,3-b]piridin-6-karboksamida;
cis-N-(3-hidroksitetrahidropiran-4-il)-4-(3-fluorobenzil)-1-metil-1H-pirolo[2,3-b]piridin-6-karboksamida (Izomer-I);
cis-N-(3-hidroksitetrahidropiran-4-il)-4-(3-fluorobenzil)-1-metil-1H-pirolo[2,3-b]piridin-6-karboksamida (Izomer-II);
Racemskog cis-N-(4-hidroksitetrahidropiran-3-il)-4-(4-fluorobenzil)-1-metil-1H-pirolo[2,3-b]piridin-6-karboksamida;
cis-N-(4-hidroksitetrahidropiran-3-il)-4-(4-fluorobenzil)-1-metil-1H-pirolo[2,3-b]piridin-6-karboksamida (Izomer-I);
cis-N-(4-hidroksitetrahidropiran-3-il)-4-(4-fluorobenzil)-1-metil-1H-pirolo[2,3-b]piridin-6-karboksamida (Izomer-II);
Racemskog trans-N-(4-hidroksitetrahidropiran-3-il)-4-(4-fluorobenzil)-1-metil-1H-pirolo[2,3-b]piridin-6-karboksamida;
trans-N-(4-hidroksitetrahidropiran-3-il)-4-(4-fluorobenzil)-1-metil-1H-pirolo[2,3-b]piridin-6-karboksamida (Izomer-I);
trans-N-(4-hidroksitetrahidropiran-3-il)-4-(4-fluorobenzil)-1-metil-1H-pirolo[2,3-b]piridin-6-karboksamida (Izomer-II);
Racemskog cis-N-(4-hidroksitetrahidropiran-3-il)-4-(4-metoksibenzil)-1-metil-1H-pirolo[2,3-b]piridin-6-karboksamida;
cis-N-(4-hidroksitetrahidropiran-3-il)-4-(4-metoksibenzil)-1-metil-1H-pirolo[2,3-b]piridin-6-karboksamida (Izomer-I);
cis-N-(4-hidroksitetrahidropiran-3-il)-4-(4-metoksibenzil)-1-metil-1H-pirolo[2,3-b]piridin-6-karboksamida (Izomer-II);
Racemskog trans-N-(4-hidroksitetrahidropiran-3-il)-4-(4-metoksibenzil)-1-metil-1H-pirolo[2,3-b]piridin-6-karboksamida;
trans-N-(4-hidroksitetrahidropiran-3-il)-4-(4-metoksibenzil)-1-metil-1H-pirolo[2,3-b]piridin-6-karboksamida (Izomer-I);
trans-N-(4-hidroksitetrahidropiran-3-il)-4-(4-metoksibenzil)-1-metil-1H-pirolo[2,3-b]piridin-6-karboksamida (Izomer-II);
Racemskog cis-N-(4-hidroksitetrahidropiran-3-il)-4-(2-metilpiridin-5-ilmetil)-1-metil-1H-pirolo[2,3-b]piridin-6-karboksamida;
cis-N-(4-hidroksitetrahidropiran-3-il)-4-(2-metilpiridin-5-ilmetil)-1-metil-1H-pirolo[2,3-b]piridin-6-karboksamida (Izomer-I);
cis-N-(4-hidroksitetrahidropiran-3-il)-4-(2-metilpiridin-5-ilmetil)-1-metil-1H-pirolo[2,3-b]piridin-6-karboksamida (Izomer-II);
Racemskog trans-N-(4-hidroksitetrahidropiran-3-il)-4-(2-metilpiridin-5-ilmetil)-1-metil-1H-pirolo[2,3-b]piridin-6-karboksamida;
trans-N-(4-hidroksitetrahidropiran-3-il)-4-(2-metilpiridin-5-ilmetil)-1-metil-1H-pirolo[2,3-b]piridin-6-karboksamida (Izomer-I);
trans-N-(4-hidroksitetrahidropiran-3-il)-4-(2-metilpiridin-5-ilmetil)-1-metil-1H-pirolo[2,3-b]piridin-6-karboksamida (Izomer-II);
(3S,4S)-N-(4-hidroksitetrahidropiran-3-il)-4-(4-fluorobenzil)-1-metil-1H-pirolo[2,3-b]piridin-6-karboksamida;
(3S,4S)-N-(4-hidroksitetrahidropiran-3-il)-4-(4-metoksibenzil)-1-metil-1H-pirolo[2,3-b]piridin-6-karboksamida;
(3S,4S)-N-(4-hidroksitetrahidropiran-3-il)-4-(2-metilpiridin-5-ilmetil)-1-metil-1H-pirolo[2,3-b]piridin-6-karboksamida;
N-[(1S,2S)-2-hidroksicikloheksil]-4-(2-kloropiridin-5-ilmetil)-1-metil-2,3-dihidro-1H-pirolo[2,3-b]piridin-6-karboksamida;
N-[(1S,2S)-2-hidroksicikloheksil]-4-(2-fluoropiridin-4-ilmetil)-1-metil-2,3-dihidro-1H-pirolo[2,3-b]piridin-6-karboksamida;
N-[(1S,2S)-2-hidroksicikloheksil]-4-(2-fluoropiridin-5-ilmetil)-1-metil-2,3-dihidro-1H-pirolo[2,3-b]piridin-6-karboksamida;
N-[(1S,2S)-2-hidroksicikloheksil]-1-metil-(6-metilpiridin-3-ilmetil)-2,3-dihidro-1H-pirolo[2,3-b]piridin-6-karboksamida;
N-[(1S,2S)-2-hidroksicikloheksil]-4-(4-fluorobenzil)-1-metil-2,3-dihidro-1H-pirolo[2,3-b]piridin-6-karboksamida;
N-[(1S,2S)-2-hidroksicikloheksil]-4-(4-metoksibenzil)-1-metil-2,3-dihidro-1H-pirolo[2,3-b]piridin-6-karboksamida;
N-[(1S,2S)-2-hidroksicikloheksil]-4-(2’-fluoro-[2,5]bipiridinil-5-ilmetil)-1-metil-2,3-dihidro-1H-pirolo[2,3-b]piridin-6-karboksamida;
N-[(1S,2S)-2-hidroksicikloheksil]-4-(2,3-difluorobenzil)-1-metil-2,3-dihidro-1H-pirolo[2,3-b]piridin-6-karboksamida;
N-[(1S,2S)-2-hidroksicikloheksil]-4-(2-metil-4-piridinilmetil)-1-metil-2,3-dihidro-1H-pirolo [2,3-b]piridin-6-karboksamida;
cis-N-(4-hidroksitetrahidropiran-3-il)-4-(4-fluorobenzil)-1-metil-2,3-dihidro-1H-pirolo[2,3-b]piridin-6-karboksamida (Izomer-I);
cis-N-(4-hidroksitetrahidropiran-3-il)-4-(4-fluorobenzil)-1-metil-2,3-dihidro-1H-pirolo[2,3-b]piridin-6-karboksamida (Izomer-II);
Racemskog cis-N-(4-hidroksitetrahidropiran-3-il)-4-(4-metoksibenzil)-1-metil-2,3-dihidro-1H-pirolo[2,3-b]piridin-6-karboksamida;
(3S,4S)-N-(4-hidroksitetrahidropiran-3-il)-4-(4-fluorobenzil)-1-metil-2,3-dihidro-1H-pirolo[2,3-b]piridin-6-karboksamida;
(3S,4S)-N-(4-hidroksitetrahidropiran-3-il)-4-(4-metoksibenzil)-1-metil-2,3-dihidro-1H-pirolo[2,3-b]piridin-6-karboksamida;
(3S,4S)-N-(4-hidroksitetrahidropiran-3-il)-4-(2-metilpiridin-5-ilmetil)-1-metil-2,3-dihidro-1H-pirolo[2,3-b]piridin-6-karboksamida;
N-[(1S,2S)-2-hidroksicikloheksil]-4-(4-fluorobenzil)-5,6,7,8-tetrahidro[1,7]naftiridin-2-karboksamid hidroklorida;
N-[(1S,2S)-2-hidroksicikloheksil]-4-(4-fluorobenzil)-5,6,7,8-tetrahidro[1,7]naftiridin-2-karboksamida;
N-[(1S,2S)-2-hidroksicikloheksil]-4-(4-klorobenzil)-5,6,7,8-tetrahidro[1,7]naftiridin-2-karboksamid hidroklorida;
N-[(1S,2S)-2-hidroksicikloheksil]-4-(4-klorobenzil)-5,6,7,8-tetrahidro[1,7]naftiridin-2-karboksamida;
N-[(1S,2S)-2-hidroksicikloheksil]-4-(3-fluorobenzil)-5,6,7,8-tetrahidro[1,7]naftiridin-2-karboksamid hidroklorida;
N-[(1S,2S)-2-hidroksicikloheksil]-4-(3-fluorobenzil)-5,6,7,8-tetrahidro[1,7]naftiridin-2-karboksamida;
N-[(1S,2S)-2-hidroksicikloheksil]-4-[4-(1-metil-1H-pirazol-4-il)-benzil]-5,6,7,8-tetrahidro[1,7]naftiridin-2-karboksamid hidroklorida;
N-[(1S,2S)-2-hidroksicikloheksil]-4-[4-(1-metil-1H-pirazol-4-il)-benzil]-5,6,7,8-tetrahidro[1,7]naftiridin-2-karboksamida;
N-[(1S,2S)-2-hidroksicikloheksil]-4-(2-fluoropiridin-5-ilmetil)-5,6,7,8-tetrahidro[1,7]naftiridin-2-karboksamid hidroklorida;
N-[(1S,2S)-2-hidroksicikloheksil]-4-(2-fluoropiridin-5-ilmetil)-5,6,7,8-tetrahidro[1,7]naftiridin-2-karboksamida;
N-[(1S,2S)-2-hidroksicikloheksil]-4-(4-metoksibenzil)-5,6,7,8-tetrahidro[1,7]naftiridin-2-karboksamid hidroklorida;
N-[(1S,2S)-2-hidroksicikloheksil]-4-(4-metoksibenzil)-5,6,7,8-tetrahidro[1,7]naftiridin-2-karboksamida;
N-[(1S,2S)-2-hidroksicikloheksil]-4-(2-fluoropiridin-4-ilmetil)-5,6,7,8-tetrahidro[1,7]naftiridin-2-karboksamid hidroklorida;
N-[(1S,2S)-2-hidroksicikloheksil]-4-(2-fluoropiridin-4-ilmetil)-5,6,7,8-tetrahidro[1,7]naftiridin-2-karboksamida;
N-[(1S,2S)-2-hidroksicikloheksil]-4-(4-pirazol-1-ilbenzil)-5,6,7,8-tetrahidro[1,7]naftiridin-2-karboksamid hidroklorida;
N-[(1S,2S)-2-hidroksicikloheksil]-4-(4-pirazol-1-ilbenzil)-5,6,7,8-tetrahidro[1,7]naftiridin-2-karboksamida;
N-[(1S,2S)-2-hidroksicikloheksil]-4-(4-fluorobenzil)-7-metil-5,6,7,8-tetrahidro[1,7]naftiridin-2-karboksamida;
N-[(1S,2S)-2-hidroksicikloheksil]-4-(4-fluorobenzil)-7-etil-5,6,7,8-tetrahidro[1,7]naftiridin-2-karboksamida;
trans-N-(3-hidroksitetrahidropiran-4-il)-4-[4-(tiazol-4-il)benzil]-5,6,7,8-tetrahidro[1,7]naftiridin-2-karboksamid hidroklorida (Izomer-II);
Racemskog cis-N-(3-hidroksitetrahidropiran-4-il)-4-[4-(tiazol-4-il)benzil]-5,6,7,8-tetrahidro[1,7]naftiridin-2-karboksamid hidroklorida;
cis-N-(3-hidroksitetrahidropiran-4-il)-4-[4-(tiazol-4-il)benzil]-5,6,7,8-tetrahidro[1,7]naftiridin-2-karboksamid hidroklorida (Izomer-I);
cis-N-(3-hidroksitetrahidropiran-4-il)-4-[4-(tiazol-4-il)benzil]-5,6,7,8-tetrahidro[1,7]naftiridin-2-karboksamid hidroklorida (Izomer-II);
Racemskog trans-N-(3-hidroksitetrahidropiran-4-il)-4-[4-(tiazol-4-il)benzil]-5,6,7,8-tetrahidro[1,7]naftiridin-2-karboksamid hidroklorida;
trans-N-(3-hidroksitetrahidropiran-4-il)-4-[4-(tiazol-4-il)benzil]-5,6,7,8-tetrahidro[1,7]naftiridin-2-karboksamid hidroklorida (Izomer-I);
Racemskog cis-N-(3-hidroksitetrahidropiran-4-il)-4-[4-(tiazol-4-il)benzil]-5,6,7,8-tetrahidro[1,7]naftiridin-2-karboksamida;
cis-N-(3-hidroksitetrahidropiran-4-il)-4-[4-(tiazol-4-il)benzil]-5,6,7,8-tetrahidro[1,7]naftiridin-2-karboksamida (Izomer-I);
cis-N-(3-hidroksitetrahidropiran-4-il)-4-[4-(tiazol-4-il)benzil]-5,6,7,8-tetrahidro[1,7]naftiridin-2-karboksamida (Izomer-II);
Racemskog trans-N-(3-hidroksitetrahidropiran-4-il)-4-[4-(tiazol-4-il)benzil]-5,6,7,8-tetrahidro[1,7]naftiridin-2-karboksamida;
trans-N-(3-hidroksitetrahidropiran-4-il)-4-[4-(tiazol-4-il)benzil]-5,6,7,8-tetrahidro[1,7]naftiridin-2-karboksamida (Izomer-I);
trans-N-(3-hidroksitetrahidropiran-4-il)-4-[4-(tiazol-4-il)benzil]-5,6,7,8-tetrahidro[1,7]naftiridin-2-karboksamida (Izomer-II);
trans-N-(3-hidroksitetrahidropiran-4-il)-4-(4-fluorobenzil)-5,6,7,8-tetrahidro[1,7]naftiridin-2-karboksamid hidroklorida (Izomer-II);
Racemskog cis-N-(3-hidroksitetrahidropiran-4-il)-4-(4-fluorobenzil)-5,6,7,8-tetrahidro[1,7]naftiridin-2-karboksamid hidroklorida;
cis-N-(3-hidroksitetrahidropiran-4-il)-4-(4-fluorobenzil)-5,6,7,8-tetrahidro[1,7]naftiridin-2-karboksamid hidroklorida (Izomer-I);
cis-N-(3-hidroksitetrahidropiran-4-il)-4-(4-fluorobenzil)-5,6,7,8-tetrahidro[1,7]naftiridin-2-karboksamid hidroklorida (Izomer-II);
Racemskog trans-N-(3-hidroksitetrahidropiran-4-il)-4-(4-fluorobenzil)-5,6,7,8-tetrahidro[1,7]naftiridin-2-karboksamid hidroklorida;
trans-N-(3-hidroksitetrahidropiran-4-il)-4-(4-fluorobenzil)-5,6,7,8-tetrahidro[1,7]naftiridin-2-karboksamid hidroklorida (Izomer-I);
Racemskog cis-N-(3-hidroksitetrahidropiran-4-il)-4-(4-fluorobenzil)-5,6,7,8-tetrahidro[1,7]naftiridin-2-karboksamida;
cis-N-(3-hidroksitetrahidropiran-4-il)-4-(4-fluorobenzil)-5,6,7,8-tetrahidro[1,7]naftiridin-2-karboksamida (Izomer-I);
cis-N-(3-hidroksitetrahidropiran-4-il)-4-(4-fluorobenzil)-5,6,7,8-tetrahidro[1,7]naftiridin-2-karboksamida (Izomer-II);
Racemskog trans-N-(3-hidroksitetrahidropiran-4-il)-4-(4-fluorobenzil)-5,6,7,8-tetrahidro[1,7]naftiridin-2-karboksamida;
trans-N-(3-hidroksitetrahidropiran-4-il)-4-(4-fluorobenzil)-5,6,7,8-tetrahidro[1,7]naftiridin-2-karboksamida (Izomer-I);
trans-N-(3-hidroksitetrahidropiran-4-il)-4-(4-fluorobenzil)-5,6,7,8-tetrahidro[1,7]naftiridin-2-karboksamida (Izomer-II);
trans-N-(3-hidroksitetrahidropiran-4-il)-4-(4-pirazol-1-ilbenzil)-5,6,7,8-tetrahidro[1,7]naftiridin-2-karboksamid hidroklorida (Izomer-II);
Racemskog trans-N-(3-hidroksitetrahidropiran-4-il)-4-(4-pirazol-1-ilbenzil)-5,6,7,8-tetrahidro[1,7]naftiridin-2-karboksamid hidroklorida;
trans-N-(3-hidroksitetrahidropiran-4-il)-4-(4-pirazol-1-ilbenzil)-5,6,7,8-tetrahidro[1,7]naftiridin-2-karboksamid hidroklorida (Izomer-I);
Racemskog cis-N-(3-hidroksitetrahidropiran-4-il)-4-(4-pirazol-1-ilbenzil)-5,6,7,8-tetrahidro[1,7]naftiridin-2-karboksamid hidroklorida;
cis-N-(3-hidroksitetrahidropiran-4-il)-4-(4-pirazol-1-ilbenzil)-5,6,7,8-tetrahidro[1,7]naftiridin-2-karboksamid hidroklorida (Izomer-I);
cis-N-(3-hidroksitetrahidropiran-4-il)-4-(4-pirazol-1-ilbenzil)-5,6,7,8-tetrahidro[1,7]naftiridin-2-karboksamid hidroklorida (Izomer-II);
Racemskog trans-N-(3-hidroksitetrahidropiran-4-il)-4-(4-pirazol-1-ilbenzil)-5,6,7,8-tetrahidro[1,7]naftiridin-2-karboksamida;
trans-N-(3-hidroksitetrahidropiran-4-il)-4-(4-pirazol-1-ilbenzil)-5,6,7,8-tetrahidro[1,7]naftiridin-2-karboksamida (Izomer-I);
trans-N-(3-hidroksitetrahidropiran-4-il)-4-(4-pirazol-1-ilbenzil)-5,6,7,8-tetrahidro[1,7]naftiridin-2-karboksamida (Izomer-II);
Racemskog cis-N-(3-hidroksitetrahidropiran-4-il)-4-(4-pirazol-1-ilbenzil)-5,6,7,8-tetrahidro[1,7]naftiridin-2-karboksamida;
cis-N-(3-hidroksitetrahidropiran-4-il)-4-(4-pirazol-1-ilbenzil)-5,6,7,8-tetrahidro[1,7]naftiridin-2-karboksamida (Izomer-I);
cis-N-(3-hidroksitetrahidropiran-4-il)-4-(4-pirazol-1-ilbenzil)-5,6,7,8-tetrahidro[1,7]naftiridin-2-karboksamida (Izomer-II);
cis-N-(4-hidroksitetrahidropiran-3-il)-4-(4-fluorobenzil)-5,6,7,8-tetrahidro[1,7]naftiridin-2-karboksamid hidroklorida (Izomer-I);
cis-N-(4-hidroksitetrahidropiran-3-il)-4-(4-fluorobenzil)-5,6,7,8-tetrahidro[1,7]naftiridin-2-karboksamid hidroklorida (Izomer-II);
Racemskog cis-N-(4-hidroksitetrahidropiran-3-il)-4-(4-fluorobenzil)-5,6,7,8-tetrahidro[1,7]naftiridin-2-karboksamid hidroklorida;
Racemskog trans-N-(4-hidroksitetrahidropiran-3-il)-4-(4-fluorobenzil)-5,6,7,8-tetrahidro[1,7]naftiridin-2-karboksamid hidroklorida;
trans-N-(4-hidroksitetrahidropiran-3-il)-4-(4-fluorobenzil)-5,6,7,8-tetrahidro[1,7]naftiridin-2-karboksamid hidroklorida (Izomer-I);
trans-N-(4-hidroksitetrahidropiran-3-il)-4-(4-fluorobenzil)-5,6,7,8-tetrahidro[1,7]naftiridin-2-karboksamid hidroklorida (Izomer-II);
Racemskog cis-N-(4-hidroksitetrahidropiran-3-il)-4-(4-fluorobenzil)-5,6,7,8-tetrahidro[1,7]naftiridin-2-karboksamida;
cis-N-(4-hidroksitetrahidropiran-3-il)-4-(4-fluorobenzil)-5,6,7,8-tetrahidro[1,7]naftiridin-2-karboksamida (Izomer-I);
cis-N-(4-hidroksitetrahidropiran-3-il)-4-(4-fluorobenzil)-5,6,7,8-tetrahidro[1,7]naftiridin-2-karboksamida (Izomer-II);
Racemskog trans-N-(4-hidroksitetrahidropiran-3-il)-4-(4-fluorobenzil)-5,6,7,8-tetrahidro[1,7]naftiridin-2-karboksamida;
trans-N-(4-hidroksitetrahidropiran-3-il)-4-(4-fluorobenzil)-5,6,7,8-tetrahidro[1,7]naftiridin-2-karboksamida (Izomer-I);
trans-N-(4-hidroksitetrahidropiran-3-il)-4-(4-fluorobenzil)-5,6,7,8-tetrahidro[1,7]naftiridin-2-karboksamida (Izomer-II);
Racemskog cis-N-(4-hidroksitetrahidropiran-3-il)-4-(4-pirazol-1-ilbenzil)-5,6,7,8-tetrahidro[1,7]naftiridin-2-karboksamid hidroklorida;
cis-N-(4-hidroksitetrahidropiran-3-il)-4-(4-pirazol-1-ilbenzil)-5,6,7,8-tetrahidro[1,7]naftiridin-2-karboksamid hidroklorida (Izomer-I);
cis-N-(4-hidroksitetrahidropiran-3-il)-4-(4-pirazol-1-ilbenzil)-5,6,7,8-tetrahidro[1,7]naftiridin-2-karboksamid hidroklorida (Izomer-II);
Racemskog trans-N-(4-hidroksitetrahidropiran-3-il)-4-(4-pirazol-1-ilbenzil)-5,6,7,8-tetrahidro[1,7]naftiridin-2-karboksamid hidroklorida;
trans-N-(4-hidroksitetrahidropiran-3-il)-4-(4-pirazol-1-ilbenzil)-5,6,7,8-tetrahidro[1,7]naftiridin-2-karboksamid hidroklorida (Izomer-I);
trans-N-(4-hidroksitetrahidropiran-3-il)-4-(4-pirazol-1-ilbenzil)-5,6,7,8-tetrahidro[1,7]naftiridin-2-karboksamid hidroklorida (Izomer-II);
Racemskog cis-N-(4-hidroksitetrahidropiran-3-il)-4-(4-pirazol-1-ilbenzil)-5,6,7,8-tetrahidro[1,7]naftiridin-2-karboksamida;
cis-N-(4-hidroksitetrahidropiran-3-il)-4-(4-pirazol-1-ilbenzil)-5,6,7,8-tetrahidro[1,7]naftiridin-2-karboksamida (Izomer-I);
cis-N-(4-hidroksitetrahidropiran-3-il)-4-(4-pirazol-1-ilbenzil)-5,6,7,8-tetrahidro[1,7]naftiridin-2-karboksamida (Izomer-II);
Racemskog trans-N-(4-hidroksitetrahidropiran-3-il)-4-(4-pirazol-1-ilbenzil)-5,6,7,8-tetrahidro[1,7]naftiridin-2-karboksamida;
trans-N-(4-hidroksitetrahidropiran-3-il)-4-(4-pirazol-1-ilbenzil)-5,6,7,8-tetrahidro[1,7]naftiridin-2-karboksamida (Izomer-I);
trans-N-(4-hidroksitetrahidropiran-3-il)-4-(4-pirazol-1-ilbenzil)-5,6,7,8-tetrahidro[1,7]naftiridin-2-karboksamida (Izomer-II);
N-[(1S,2S)-2-hidroksicikloheksil]-8-(4-fluorobenzil)-2,3-dihidro-[1,4]dioksino[2,3-b]piridin-6-karboksamida;
N-[(1S,2S)-2-hidroksicikloheksil]-8-(4-metoksibenzil)-2,3-dihidro-[1,4]dioksino[2,3-b]piridin-6-karboksamida;
N-[(1S,2S)-2-hidroksicikloheksil]-8-(2-kloropiridin-5-ilmetil)-2,3-dihidro-[1,4]dioksino[2,3-b]piridin-6-karboksamida;
N-[(1S,2S)-2-hidroksicikloheksil]-8-[4-(1-metil-1H-pirazol-4-il)-benzil]-2,3-dihidro-[1,4]dioksino[2,3-b]piridin-6-karboksamida;
N-[(1S,2S)-2-hidroksicikloheksil]-8-(2,3-difluorobenzil)-2,3-dihidro-[1,4]dioksino[2,3-b]piridin-6-karboksamida;
N-[(1S,2S)-2-hidroksicikloheksil]-8-(1-metil-1H-pirazol-4-ilmetil)-2,3-dihidro-[1,4]dioksino[2,3-b]piridin-6-karboksamida;
N-[(1S,2S)-2-hidroksicikloheksil]-8-[4-(pirazol-1-il)benzil]-2,3-dihidro-[1,4]dioksino[2,3-b]piridin-6-karboksamida;
N-[(1S,2S)-2-hidroksicikloheksil]-8-(2-metilpiridin-5-ilmetil)-2,3-dihidro-[1,4]dioksino[2,3-b]piridin-6-karboksamida;
N-[(1S,2S)-2-hidroksicikloheksil]-8-(2-fluoropiridin-5-ilmetil)-2,3-dihidro-[1,4]dioksino[2,3-b]piridin-6-karboksamida;
N-[(1S,2S)-2-hidroksicikloheksil]-8-(2-fluoropiridin-4-ilmetil)-2,3-dihidro-[1,4]dioksino[2,3-b]piridin-6-karboksamida;
trans-N-(3-hidroksitetrahidropiran-4-il)-8-(4-fluorobenzil)-2,3-dihidro-[1,4]dioksino[2,3-b]piridin-6-karboksamida (Izomer-II);
cis-N-(3-hidroksitetrahidropiran-4-il)-8-(4-fluorobenzil)-2,3-dihidro-[1,4]dioksino[2,3-b]piridin-6-karboksamida (Izomer-II);
Racemskog cis-N-(3-hidroksitetrahidropiran-4-il)-8-(4-fluorobenzil)-2,3-dihidro-[1,4]dioksino[2,3-b]piridin-6-karboksamida;
cis-N-(3-hidroksitetrahidropiran-4-il)-8-(4-fluorobenzil)-2,3-dihidro-[1,4]dioksino[2,3-b]piridin-6-karboksamida (Izomer-I);
Racemskog trans-N-(3-hidroksitetrahidropiran-4-il)-8-(4-fluorobenzil)-2,3-dihidro-[1,4]dioksino[2,3-b]piridin-6-karboksamida;
trans-N-(3-hidroksitetrahidropiran-4-il)-8-(4-fluorobenzil)-2,3-dihidro-[1,4]dioksino[2,3-b]piridin-6-karboksamida (Izomer-I);
(3S,4S)-N-(4-hidroksitetrahidropiran-3-il)-8-(4-metoksibenzil)-2,3-dihidro-[1,4]dioksino[2,3-b]piridin-6-karboksamida;
(3S,4S)-N-(4-hidroksitetrahidropiran-3-il)-8-(4-fluorobenzil)-2,3-dihidro-[1,4]dioksino[2,3-b]piridin-6-karboksamida;
(3S,4S)-N-(4-hidroksitetrahidropiran-3-il)-8-(2-kloropiridin-5-ilmetil)-2,3-dihidro-[1,4]dioksino[2,3-b]piridin-6-karboksamida;
(3S,4S)-N-(4-hidroksitetrahidropiran-3-il)-8-(2-metilpiridin-5-ilmetil)-2,3-dihidro-[1,4]dioksino [2,3-b]piridin-6-karboksamida;
Racemskog cis-N-(4-hidroksitetrahidropiran-3-il)-8-(4-fluorobenzil)-2,3-dihidro-[1,4]dioksino[2,3-b]piridin-6-karboksamida;
Racemskog cis-N-(4-hidroksitetrahidropiran-3-il)-8-(4-metoksibenzil)-2,3-dihidro-[1,4]dioksino[2,3-b]piridin-6-karboksamida;
N-[(1S,2S)-2-hidroksicikloheksil]-8-(4-fluorobenzil)-4-metil-2H-pirido[3,2-b] [1,4]oksazin-6-karboksamida;
N-[(1S,2S)-2-hidroksicikloheksil]-8-(3-fluorobenzil)-4-metil-2H-pirido[3,2-b] [1,4]oksazin-6-karboksamida;
N-[(1S,2S)-2-hidroksicikloheksil]-8-[4-(1-metil-1H-pirazol-4-il)benzil]-4-metil-2H-pirido[3,2-b][1,4]oksazin-6-karboksamida;
N-[(1S,2S)-2-hidroksicikloheksil]-8-(2-fluoropiridin-4-ilmetil)-4-metil-2H-pirido[3,2-b][1,4]oksazin-6-karboksamida;
trans-N-(3-hidroksitetrahidropiran-4-il)-8-(4-fluorobenzil)-4-metil-2H-pirido[3,2-b][1,4]oksazin-6-karboksamida (Izomer-II);
Racemskog cis-N-(3-hidroksitetrahidropiran-4-il)-8-(4-fluorobenzil)-4-metil-2H-pirido[3,2-b][1,4]oksazin-6-karboksamida;
cis-N-(3-hidroksitetrahidropiran-4-il)-8-(4-fluorobenzil)-4-metil-2H-pirido[3,2-b][1,4]oksazin-6-karboksamida (Izomer-I);
Racemskog trans-N-(3-hidroksitetrahidropiran-4-il)-8-(4-fluorobenzil)-4-metil-2H-pirido[3,2-b][1,4]oksazin-6-karboksamida;
trans-N-(3-hidroksitetrahidropiran-4-il)-8-(4-fluorobenzil)-4-metil-2H-pirido[3,2-b][1,4]oksazin-6-karboksamida (Izomer-I);
trans-N-(3-hidroksitetrahidropiran-4-il)-8-(4-fluorobenzil)-4-metil-2H-pirido[3,2-b][1,4]oksazin-6-karboksamida (Izomer-II);
trans-N-(3-hidroksitetrahidropiran-4-il)-8-(4-metoksibenzil)-4-metil-2H-pirido[3,2-b][1,4]oksazin-6-karboksamida (Izomer-II);
Racemskog trans-N-(3-hidroksitetrahidropiran-4-il)-8-(4-metoksibenzil)-4-metil-2H-pirido[3,2-b][1,4]oksazin-6-karboksamida;
trans-N-(3-hidroksitetrahidropiran-4-il)-8-(4-metoksibenzil)-4-metil-2H-pirido[3,2-b][1,4]oksazin-6-karboksamida (Izomer-I);
Racemskog cis-N-(3-hidroksitetrahidropiran-4-il)-8-(4-metoksibenzil)-4-metil-2H-pirido[3,2-b][1,4]oksazin-6-karboksamida;
cis-N-(3-hidroksitetrahidropiran-4-il)-8-(4-metoksibenzil)-4-metil-2H-pirido[3,2-b][1,4]oksazin-6-karboksamida (Izomer-I);
cis-N-(3-hidroksitetrahidropiran-4-il)-8-(4-metoksibenzil)-4-metil-2H-pirido[3,2-b][1,4]oksazin-6-karboksamida (Izomer-II);
N-[(1S,2S)-2-hidroksicikloheksil]-8-(2-kloropiridin-5-ilmetil)-4-metil-2H-pirido[3,2-b][1,4]oksazin-6-karboksamida;
N-[(1S,2S)-2-hidroksicikloheksil]-8-(4-metoksibenzil)-4-metil-2H-pirido[3,2-b][1,4]oksazin-6-karboksamida;
N-[(1S,2S)-2-hidroksicikloheksil]-8-(2-metilpiridin-5-ilmetil)-4-metil-2H-pirido[3,2-b][1,4]oksazin-6-karboksamida;
N-[(1S,2S)-2-hidroksicikloheksil]-8-[4-pirazol-1-ilbenzil]-4-metil-2H-pirido[3,2-b][1,4]oksazin-6-karboksamida;
N-[(1S,2S)-2-hidroksicikloheksil]-4-metil-8-(1-metil-1H-pirazol-4-ilmetil)-2H-pirido [3,2-b][1,4]oksazin-6-karboksamida;
Racemskog cis-N-(4-hidroksitetrahidropiran-3-il)-8-(4-fluorobenzil)-4-metil-2H-pirido[3,2-b][1,4]oksazin-6-karboksamida;
Racemskog cis-N-(4-hidroksitetrahidropiran-3-il)-8-(4-metoksibenzil)-4-metil-2H-pirido[3,2-b][1,4]oksazin-6-karboksamida;
(3S,4S)-N-(4-hidroksitetrahidropiran-3-il)-8-(4-fluorobenzil)-4-metil-2H-pirido[3,2-b][1,4]oksazin-6-karboksamida;
(3S,4S)-N-(4-hidroksitetrahidropiran-3-il)-8-(4-metoksibenzil)-4-metil-2H-pirido[3,2-b][1,4]oksazin-6-karboksamida;
(3S,4S)-N-(4-hidroksitetrahidropiran-3-il)-8-(4-pirazol-1-ilbenzil)-4-metil-2H-pirido[3,2-b][1,4]oksazin-6-karboksamida;
(3S,4S)-N-(4-hidroksitetrahidropiran-3-il)-4-metil-8-(1-metil-1H-pirazol-4-ilmetil)-2H-pirido[3,2-b][1,4]oksazin-6-karboksamida;
N-[(1S,2S)-2-hidroksicikloheksil]-7-(4-fluorobenzil)-1-metil-1H-pirolo[3,2-b]piridin-5-karboksamida;
Racemskog cis-N-(3-hidroksitetrahidropiran-4-il)-7-(2-kloropiridin-5-ilmetil)-1-metil-1H-pirolo[3,2-b]piridin-5-karboksamida;
cis-N-(3-hidroksitetrahidropiran-4-il)-7-(2-kloropiridin-5-ilmetil)-1-metil-1H-pirolo [3,2-b]piridin-5-karboksamida (Izomer-I);
cis-N-(3-hidroksitetrahidropiran-4-il)-7-(2-kloropiridin-5-ilmetil)-1-metil-1H-pirolo [3,2-b]piridin-5-karboksamida (Izomer-II);
Racemskog trans-N-(3-hidroksitetrahidropiran-4-il)-7-(2-kloropiridin-5-ilmetil)-1-metil-1H-pirolo[3,2-b]piridin-5-karboksamida;
trans-N-(3-hidroksitetrahidropiran-4-il)-7-(2-kloropiridin-5-ilmetil)-1-metil-1H-pirolo[3,2-b]piridin-5-karboksamida (Izomer-I);
trans-N-(3-hidroksitetrahidropiran-4-il)-7-(2-kloropiridin-5-ilmetil)-1-metil-1H-pirolo[3,2-b]piridin-5-karboksamida (Izomer-II);
N-[(1S,2S)-2-hidroksicikloheksil]-7-(2-kloropiridin-5-ilmetil)-1-metil-1H-pirolo[3,2-b]piridin-5-karboksamida;
Racemskog cis-N-(4-hidroksitetrahidropiran-3-il)-7-(4-metoksibenzil)-1-metil-1H-pirolo[3,2-b]piridin-5-karboksamida;
(3S,4S)-N-(4-hidroksitetrahidropiran-3-il)-7-(4-fluorobenzil)-1-metil-1H-pirolo[3,2-b]piridin-5-karboksamida; i
(3S,4S)-N-(4-hidroksitetrahidropiran-3-il)-7-(4-metoksibenzil)-1-metil-1H-pirolo[3,2-b]piridin-5-karboksamida;
ili njihove farmaceutski prihvatljive soli.
5. Farmaceutski pripravak koji sadrži spoj formule (I) ili njegovu farmaceutski prihvatljivu sol prema bilo kojem od patentnih zahtjeva 1 do 4 i farmaceutski prihvatljive ekscipijente.
6. Farmaceutski pripravak prema patentnom zahtjevu 5 za uporabu u liječenju bolesti ili poremećaja posredovanog muskarinskim M1 receptorom, naznačen time što je navedena bolest ili poremećaj odabran iz grupe koja se sastoji od kognitivnih poremećaja, boli ili poremećaja spavanja.
7. Kombinacija koja sadrži spoj prema bilo kojem od patentnih zahtjeva 1 do 4 sa jednim ili više terapijskih sredstava odabranih od inhibitora acetilkolinesteraze i antagonista NMDA receptora.
8. Kombinacija prema patentnom zahtjevu 7, naznačena time što su terapijska sredstva odabrana od galantamina, rivastigmina, donepezila, takrina i memantina.
9. Spoj formule (I) ili njegova farmaceutski prihvatljiva sol prema bilo kojem od patentnih zahtjeva 1 do 4 za uporabu u postupku liječenja bolesti ili poremećaja posredovanog muskarinskim M1 receptorom, naznačen time što je bolest ili poremećaj odabran iz grupe koja se sastoji od kognitivnih poremećaja, boli ili poremećaja spavanja.
10. Spoj za uporabu prema patentnom zahtjevu 9, naznačen time što je kognitivni poremećaj odabran iz grupe koja se sastoji od demencije kod Alzheimerove bolesti, demencije kod Parkinsonove bolesti, demencije kod Huntingtonove bolesti, demencije povezane sa Downovim sindromom, demencije povezane sa Tourettovim sindromom, demencije povezane sa postmenopauzom, frontotemporalne demencije, demencije sa Levi tijelima, vaskularne demencije, demencije kod HIV, demencije kod Creutzfeldt-Jakobove bolesti, supstancom-inducirane uporne demencije, demencije kod Pickove bolesti, demencije kod shizofrenije, senilne demencije i demencije kod općih medicinskih stanja.
11. Spoj formule (I) prema bilo kojem od patentnih zahtjeva 1 do 4, za uporabu u liječenju bolesti ili poremećaja odabranog od kognitivnih poremećaja, boli i poremećaja spavanja.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN201641030062 | 2016-09-02 | ||
IN201741013343 | 2017-04-13 | ||
PCT/IB2017/055238 WO2018042362A1 (en) | 2016-09-02 | 2017-08-31 | Muscarinic m1 receptor positive allosteric modulators |
EP17777380.1A EP3507289B1 (en) | 2016-09-02 | 2017-08-31 | Muscarinic m1 receptor positive allosteric modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20201539T1 true HRP20201539T1 (hr) | 2021-02-05 |
Family
ID=59982423
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20201539TT HRP20201539T1 (hr) | 2016-09-02 | 2020-09-28 | Pozitivni alosterni modulatori muskarinskog m1 receptora |
Country Status (23)
Country | Link |
---|---|
US (1) | US11040026B2 (hr) |
EP (1) | EP3507289B1 (hr) |
JP (1) | JP6629486B2 (hr) |
KR (1) | KR102017786B1 (hr) |
CN (1) | CN109952302B (hr) |
AU (1) | AU2017319609B2 (hr) |
BR (1) | BR112019003932A2 (hr) |
CA (1) | CA3034775C (hr) |
CY (1) | CY1123479T1 (hr) |
ES (1) | ES2824495T3 (hr) |
HR (1) | HRP20201539T1 (hr) |
HU (1) | HUE053586T2 (hr) |
IL (1) | IL264951B (hr) |
LT (1) | LT3507289T (hr) |
MA (1) | MA46101B1 (hr) |
MD (1) | MD3507289T2 (hr) |
MX (1) | MX2019002180A (hr) |
PL (1) | PL3507289T3 (hr) |
PT (1) | PT3507289T (hr) |
RS (1) | RS60875B1 (hr) |
SG (1) | SG11201901525XA (hr) |
SI (1) | SI3507289T1 (hr) |
WO (1) | WO2018042362A1 (hr) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3014791A1 (en) | 2016-02-16 | 2017-08-24 | Vanderbilt University | Positive allosteric modulators of the muscarinic acetylcholine receptor m1 |
US10899759B2 (en) | 2016-09-30 | 2021-01-26 | Vanderbilt University | Positive allosteric modulators of the muscarinic acetylcholine receptor M1 |
AU2018289939B2 (en) * | 2017-06-20 | 2022-06-16 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
US11236099B2 (en) | 2017-06-20 | 2022-02-01 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
CA3078164C (en) * | 2017-10-27 | 2022-11-15 | Suven Life Sciences Limited | Polycyclic amides as muscarinic m1 receptor positive allosteric modulators |
IL277071B1 (en) | 2018-03-08 | 2024-03-01 | Incyte Corp | Aminopyrizine diol compounds as PI3K–y inhibitors |
US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
CN112752760B (zh) * | 2018-09-28 | 2024-01-19 | 武田药品工业株式会社 | 杂环化合物 |
US11970483B2 (en) | 2018-09-28 | 2024-04-30 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
WO2020067457A1 (ja) | 2018-09-28 | 2020-04-02 | 武田薬品工業株式会社 | 縮合環化合物 |
MA53917A (fr) * | 2018-10-17 | 2022-01-26 | Suven Life Sciences Ltd | Dérivés de pyrrolo-pyridazine en tant que modulateurs allostériques positifs du récepteur m1 muscarinique |
US20240083907A1 (en) | 2019-10-04 | 2024-03-14 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor m4 |
WO2023114224A1 (en) | 2021-12-13 | 2023-06-22 | Sage Therapeutics, Inc. | Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090298820A1 (en) | 2008-05-28 | 2009-12-03 | Wyeth | 3-substituted-1h-pyrrolo[2,3-b]pyridine and 3-substituted-1h-pyrrolo[3,2-b]pyridine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses |
DK2512243T3 (en) * | 2009-12-17 | 2016-07-25 | Merck Sharp & Dohme | POSITIVE ALLOSTERIC QUINOLINAMIDE M1 RECEPTOR MODULATORS |
EP2575454B1 (en) | 2010-05-28 | 2018-08-29 | Merck Sharp & Dohme Corp. | Naphthalene carboxamide m1 receptor positive allosteric modulators |
EP2582676B1 (en) * | 2010-06-15 | 2016-12-14 | Merck Sharp & Dohme Corp. | Tetrahydroquinoline amide m1 receptor positive allosteric modulators |
EP2709621B1 (en) * | 2011-05-17 | 2016-11-02 | Merck Sharp & Dohme Corp. | N-linked quinolineamide m1 receptor positive allosteric modulators |
AR088082A1 (es) | 2011-10-13 | 2014-05-07 | Lilly Co Eli | Moduladores selectivos del receptor androgeno |
TW201512197A (zh) * | 2013-08-30 | 2015-04-01 | Hoffmann La Roche | 吡咯并吡啶或吡唑并吡啶衍生物 |
KR20160098500A (ko) * | 2014-01-22 | 2016-08-18 | 에프. 호프만-라 로슈 아게 | 플루오로-나프틸 유도체 |
WO2015190564A1 (ja) * | 2014-06-13 | 2015-12-17 | 武田薬品工業株式会社 | 含窒素複素環化合物 |
WO2016009297A1 (en) * | 2014-07-18 | 2016-01-21 | Pfizer Inc. | Pyridine derivatives as muscarinic m1 receptor positive allosteric modulators |
WO2016029454A1 (en) * | 2014-08-29 | 2016-03-03 | Merck Sharp & Dohme Corp. | TETRAHYDRONAPHTHYRIDINE DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE |
CA3014791A1 (en) * | 2016-02-16 | 2017-08-24 | Vanderbilt University | Positive allosteric modulators of the muscarinic acetylcholine receptor m1 |
-
2017
- 2017-08-31 KR KR1020197008723A patent/KR102017786B1/ko active IP Right Grant
- 2017-08-31 SG SG11201901525XA patent/SG11201901525XA/en unknown
- 2017-08-31 PL PL17777380T patent/PL3507289T3/pl unknown
- 2017-08-31 MX MX2019002180A patent/MX2019002180A/es unknown
- 2017-08-31 EP EP17777380.1A patent/EP3507289B1/en active Active
- 2017-08-31 MA MA46101A patent/MA46101B1/fr unknown
- 2017-08-31 LT LTEP17777380.1T patent/LT3507289T/lt unknown
- 2017-08-31 PT PT177773801T patent/PT3507289T/pt unknown
- 2017-08-31 CA CA3034775A patent/CA3034775C/en active Active
- 2017-08-31 BR BR112019003932-5A patent/BR112019003932A2/pt active Search and Examination
- 2017-08-31 CN CN201780063068.6A patent/CN109952302B/zh active Active
- 2017-08-31 WO PCT/IB2017/055238 patent/WO2018042362A1/en active Search and Examination
- 2017-08-31 MD MDE20190759T patent/MD3507289T2/ro unknown
- 2017-08-31 RS RS20201170A patent/RS60875B1/sr unknown
- 2017-08-31 AU AU2017319609A patent/AU2017319609B2/en active Active
- 2017-08-31 HU HUE17777380A patent/HUE053586T2/hu unknown
- 2017-08-31 ES ES17777380T patent/ES2824495T3/es active Active
- 2017-08-31 JP JP2019510925A patent/JP6629486B2/ja active Active
- 2017-08-31 US US16/327,742 patent/US11040026B2/en active Active
- 2017-08-31 SI SI201730419T patent/SI3507289T1/sl unknown
-
2019
- 2019-02-21 IL IL264951A patent/IL264951B/en unknown
-
2020
- 2020-09-28 HR HRP20201539TT patent/HRP20201539T1/hr unknown
- 2020-10-08 CY CY20201100944T patent/CY1123479T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
KR20190038666A (ko) | 2019-04-08 |
MA46101B1 (fr) | 2020-10-28 |
EP3507289A1 (en) | 2019-07-10 |
PL3507289T3 (pl) | 2021-01-25 |
WO2018042362A1 (en) | 2018-03-08 |
MD3507289T2 (ro) | 2020-11-30 |
NZ751569A (en) | 2020-11-27 |
PT3507289T (pt) | 2020-10-01 |
HUE053586T2 (hu) | 2021-07-28 |
ES2824495T3 (es) | 2021-05-12 |
LT3507289T (lt) | 2020-10-12 |
US11040026B2 (en) | 2021-06-22 |
KR102017786B1 (ko) | 2019-09-03 |
US20190343812A1 (en) | 2019-11-14 |
RS60875B1 (sr) | 2020-11-30 |
SI3507289T1 (sl) | 2020-11-30 |
EP3507289B1 (en) | 2020-07-15 |
SG11201901525XA (en) | 2019-03-28 |
CY1123479T1 (el) | 2022-03-24 |
WO2018042362A9 (en) | 2018-05-03 |
AU2017319609A1 (en) | 2019-03-14 |
AU2017319609B2 (en) | 2019-11-14 |
IL264951B (en) | 2021-09-30 |
CA3034775C (en) | 2020-07-14 |
MA46101A (fr) | 2019-07-10 |
MX2019002180A (es) | 2019-08-16 |
JP6629486B2 (ja) | 2020-01-15 |
JP2019526566A (ja) | 2019-09-19 |
BR112019003932A2 (pt) | 2019-05-21 |
CN109952302A (zh) | 2019-06-28 |
CA3034775A1 (en) | 2018-03-08 |
CN109952302B (zh) | 2020-11-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20201539T1 (hr) | Pozitivni alosterni modulatori muskarinskog m1 receptora | |
JP2008519794A5 (hr) | ||
HRP20161708T1 (hr) | Supstituirani 4-fenil-piridini za terapiju bolesti povezanih sa nk-1 receptorom | |
KR20010050223A (ko) | Crf 길항제 및 관련 조성물의 용도 | |
JP2007530550A5 (hr) | ||
JP2009529047A5 (hr) | ||
JP2016506419A5 (hr) | ||
JP2019507177A5 (hr) | ||
JP2009516743A5 (hr) | ||
HRP20201379T1 (hr) | Antibakterijski spojevi koji imaju široki spektar djelovanja | |
RU2003111754A (ru) | Производные пиридина с активностью ингибирования /кв-киназы (/кк-бета) | |
RU2015148189A (ru) | ПРОИЗВОДНЫЕ 2-АМИДОПИРИДО[4, 3-d]ПИРИМИДИН-5-ОНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ WEE-1 | |
JP2019514956A5 (hr) | ||
JP2014514349A5 (hr) | ||
RU2016141647A (ru) | ИНГИБИТОРЫ TrkA КИНАЗЫ, ОСНОВАННЫЕ НА НИХ КОМПОЗИЦИИ И СПОСОБЫ | |
RU2009103300A (ru) | Производные 2-бензоилимидазопиридинов, их получение и их применение в терапии | |
JP2018501315A5 (hr) | ||
IL275489B1 (en) | Chromenopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors | |
EP1145714A1 (en) | Drugs | |
JP2014520153A5 (hr) | ||
JP2018510202A5 (hr) | ||
JP2013515710A5 (hr) | ||
RU2017134110A (ru) | Производное пиразола, пригодное в качестве ингибитора рi3к | |
JP2015522592A5 (hr) | ||
JP2019530720A5 (hr) |